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A B S T R A C T
Background
Dementia is a worldwide concern. Its global prevalence is increasing. At present, there is no medication licensed to prevent or delay
the onset of dementia. Inflammation has been suggested as a key factor in dementia pathogenesis. Therefore, medications with anti-
inflammatory properties could be beneficial for dementia prevention.
Objectives
To evaluate the eDectiveness and adverse eDects of aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) for the primary or
secondary prevention of dementia.
Search methods
We searched ALOIS, the specialised register of the Cochrane Dementia and Cognitive Improvement Group up to 9 January 2020. ALOIS
contains records of clinical trials identified from monthly searches of several major healthcare databases, trial registries and grey literature
sources. We ran additional searches across MEDLINE (OvidSP), Embase (OvidSP) and six other databases to ensure that the searches were
as comprehensive and up-to-date as possible. We also reviewed citations of reference lists of included studies.
Selection criteria
We searched for randomised controlled trials (RCTs) and controlled clinical trials (CCTs) comparing aspirin or other NSAIDs with placebo
for the primary or secondary prevention of dementia. We included trials with cognitively healthy participants (primary prevention) or
participants with mild cognitive impairment (MCI) or cognitive complaints (secondary prevention).
Data collection and analysis
We used standard methodological procedures according to the Cochrane Handbook for Systematic Reviews of Interventions. We rated the
strength of evidence for each outcome using the GRADE approach.
Main results
We included four RCTs with 23,187 participants. Because of the diversity of these trials, we did not combine data to give summary estimates,
but presented a narrative description of the evidence.
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We identified one trial (19,114 participants) comparing low-dose aspirin (100 mg once daily) to placebo. Participants were aged 70 years or
older with no history of dementia, cardiovascular disease or physical disability. Interim analysis indicated no significant treatment eDect
and the trial was terminated slightly early aLer a median of 4.7 years' follow-up. There was no evidence of a diDerence in incidence of
dementia between aspirin and placebo groups (risk ratio (RR) 0.98, 95% CI 0.83 to 1.15; high-certainty evidence). Participants allocated
aspirin had higher rates of major bleeding (RR 1.37, 95% CI 1.17 to 1.60, high-certainty evidence) and slightly higher mortality (RR 1.14,
95% CI 1.01 to 1.28; high-certainty evidence). There was no evidence of a diDerence in activities of daily living between groups (RR 0.84,
95% CI 0.70 to 1.02; high-certainty evidence).
We identified three trials comparing non-aspirin NSAIDs to placebo. All three trials were terminated early due to adverse events associated
with NSAIDs reported in other trials.
One trial (2528 participants) investigated the cyclo-oxygenase-2 (COX-2) inhibitor celecoxib (200 mg twice daily) and the non-selective
NSAID naproxen (220 mg twice daily) for preventing dementia in cognitively healthy older adults with a family history of Alzheimer's disease
(AD). Median follow-up was 734 days. Combining both NSAID treatment arms, there was no evidence of a diDerence in the incidence of
AD between participants allocated NSAIDs and those allocated placebo (RR 1.91, 95% CI 0.89 to 4.10; moderate-certainty evidence). There
was also no evidence of a diDerence in rates of myocardial infarction (RR 1.21, 95% CI 0.61 to 2.40), stroke (RR 1.82, 95% CI 0.76 to 4.37) or
mortality (RR 1.37, 95% CI 0.78 to 2.43) between treatment groups (all moderate-certainty evidence).
One trial (88 participants) assessed the eDectiveness of celecoxib (200 mg or 400 mg daily) in delaying cognitive decline in participants aged
40 to 81 years with mild age-related memory loss but normal memory performance scores. Mean duration of follow-up was 17.6 months
in the celecoxib group and 18.1 months in the placebo group. There was no evidence of a diDerence between groups in test scores in any
of six cognitive domains. Participants allocated celecoxib experienced more gastrointestinal adverse events than those allocated placebo
(RR 2.66, 95% CI 1.05 to 6.75; low-certainty evidence).
One trial (1457 participants) assessed the eDectiveness of the COX-2 inhibitor rofecoxib (25 mg once daily) in delaying or preventing a
diagnosis of AD in participants with MCI. Median duration of study participation was 115 weeks in the rofecoxib group and 130 weeks in
the placebo group. There was a higher incidence of AD in the rofecoxib than the placebo group (RR 1.32, 95% CI 1.01 to 1.72; moderate-
certainty evidence). There was no evidence of a diDerence between groups in cardiovascular adverse events (RR 1.07, 95% CI 0.68 to 1.66;
moderate-certainty evidence) or mortality (RR 1.62, 95% CI 0.85 to 3.05; moderate-certainty evidence). Participants allocated rofecoxib had
more upper gastrointestinal adverse events (RR 3.53, 95% CI 1.17 to 10.68; moderate-certainty evidence). Reported annual mean diDerence
scores showed no evidence of a diDerence between groups in activities of daily living (year 1: no data available; year 2: 0.0, 95% CI –0.1 to
0.2; year 3: 0.1, 95% CI –0.1 to 0.3; year 4: 0.1, 95% CI –0.1 to 0.4; moderate-certainty evidence).
Authors' conclusions
There is no evidence to support the use of low-dose aspirin or other NSAIDs of any class (celecoxib, rofecoxib or naproxen) for the prevention
of dementia, but there was evidence of harm. Although there were limitations in the available evidence, it seems unlikely that there is any
need for further trials of low-dose aspirin for dementia prevention. If future studies of NSAIDs for dementia prevention are planned, they
will need to be cognisant of the safety concerns arising from the existing studies.
P L A I N   L A N G U A G E   S U M M A R Y
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia
Review question
The purpose of this review was to investigate if aspirin and other non-steroidal anti-inflammatory drugs (NSAIDs) could help in the
prevention of dementia.
Background
Dementia is a worldwide healthcare concern. At present, there is no medicine that is proven to delay or prevent the onset of dementia. The
biology of dementia is still poorly understood. However, there are reasons to believe that inflammation may be partly responsible for some
of the brain changes seen in dementia. There are many medicines that have anti-inflammatory properties, including aspirin and NSAIDs
that are oLen sold as pain killers. We wanted to see if these medicines had any eDect on developing dementia. These medicines have a
few potential side eDects, including heart attack and bleeding, so we also assessed for any harmful eDects of the medicines.
Study characteristics
We searched for relevant studies that had been published up to January 2020. We found four trials that met the inclusion criteria for
this review (23,187 people). One trial was undertaken in the USA and Australia and three in the USA only. The trials included diDerent
populations. One was of aspirin in healthy people with no history of dementia, cardiovascular disease or physical disability. The other
three were of NSAIDs other than aspirin and were conducted in healthy people with a family history of Alzheimer's disease, people
with self-reported memory loss and people with mild cognitive impairment (a slight but noticeable and measurable decline in cognitive
abilities, including memory and thinking skills). All of the included studies had limitations. The study of aspirin was stopped early due
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia (Review)
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to ineDectiveness. The three studies of other NSAIDs (celecoxib, naproxen and rofecoxib) were stopped early due to concerns around the
safety.
Key results and quality of the evidence
The aspirin study found that low-dose aspirin (100 mg daily) did not prevent dementia in healthy older people, but resulted in higher rates
of death and major bleeding compared to placebo (pretend tablet). We were very confident in this result. The NSAID studies did not find any
evidence of a diDerence between the NSAIDs and placebo in terms of reducing the numbers of people developing dementia. In fact, in one
of the studies, more people developed dementia in the NSAID group. One of the included NSAIDs studies reported more stomach bleeding
and another reported other stomach problems, such as pain, nausea and gastritis. Other side eDects were similar between groups. We
were moderately confident in most of the results on NSAIDs.
Conclusions
This review found no evidence to support the use of either aspirin or other NSAIDs for the prevention of dementia and, in fact, there was
some suggestion that they may cause harm. The studies had limitations, but, given the concerns over safety, further studies of low-dose
aspirin for dementia prevention seem unlikely. If future studies of NSAIDs for dementia prevention are planned, then these will need to be
mindful of the safety concerns arising from the studies included in this review and from other studies of the same medicines.
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S U M M A R Y   O F   F I N D I N G S
 
Summary of findings 1.   Aspirin compared to placebo for prevention of dementia
Aspirin compared to placebo for prevention of dementia












































Cognitive decline from baseline — — — — — Not
mea-
sured.









Health-related quality of life — — — — — Not
mea-
sured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.























































































































































Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
 
 
Summary of findings 2.   Other NSAIDs compared to placebo for the prevention of dementia in cognitively healthy older adults
Other NSAIDs compared to placebo for the prevention of dementia in cognitively healthy older adults




Anticipated absolute effects* (95% CI)Outcomes
Risk with
placebo




















Adverse events –myocardial infarc-
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Incidence of mild cognitive impair-
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Activities of daily living — — — — — Not
mea-
sured.
Health-related quality of life — — — — — Not
mea-
sured.























































































































































CI: confidence interval; NSAID: non-steroidal anti-inflammatory drug; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level due to imprecision: low event rate (i.e. total number of events was fewer than 300) (general guide).
bDowngraded one level due to risk of bias: failure to adhere to the intention-to-treat principle. Analysis for this outcome was per protocol.
 
 
Summary of findings 3.   NSAIDs (celecoxib) compared to placebo for the delay of cognitive decline in older people with age-related memory loss
NSAIDs (celecoxib) compared to placebo for the delay of cognitive decline in older people with age-related memory loss




Anticipated absolute effects* (95% CI)Outcomes






































Psychomotor speed: Trailmaking A Digital Symbol: MD 2.40, 95% CI –3.41 to 8.21; WAIS-II Digital Sym-
bol: MD –5.00, 95% CI –16.30 to 6.30.
Visuospatial functioning: WAIS-III Block Design: MD –0.70, 95% CI –7.35 to 5.95; Complex Figure, Copy:



























































































































































Executive functioning: Trailmaking B: MD 7.20, 95% CI –17.85 to 32.25; Stroop Interference: MD –4.40,
95% CI –29.42 to 20.62; F.A.S. Letter Fluency: MD –3.30, 95% CI –13.80 to 7.20.
Learning: Selective Reminding, Total Recall: MD –7.70, 95% CI –19.26 to 3.86); Verbal Paired Associa-
tions 1: MD –0.90, 95% CI –6.09 to 4.29; Benton Visual Retention: MD –0.40, 95% CI –2.26 to 1.46.
Delayed recall: Selective Reminding Delayed Recall: MD –1.50, 95% CI –3.18 to 0.18; Complex Rigure,
Recall: MD 0.50, 95% CI –4.23 to 5.23; Verbal Paired Associations 11: MD –0.70, 95% CI –2.19 to 0.79.
Language/semantic memory: Boston Naming: MD –0.20, 95% CI –3.15 to 2.75; Animal Naming: MD
3.10, 95% CI –0.31 to 6.51.
Activities of
daily living




— — — — — Not
mea-
sured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
CI: confidence interval; MD: mean difference; NSAID: non-steroidal anti-inflammatory drug; RCT: randomised controlled trial; RR: risk ratio; WAIS: Wechsler Adult Intelli-
gence Scale.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
aDowngraded one level due to imprecision: low event rate i.e. total number of events is fewer than 300 (general guide).
bDowngraded one level due to risk of bias: failure to adhere to the intention-to-treat principle. Analysis for this outcome was per protocol.
cHigher scores indicate better cognitive performance except for Trailmaking A and B, Benton Visual Retention, where lower scores indicate better performance.
 
 
Summary of findings 4.   NSAIDs (rofecoxib) for the prevention of dementia in people with mild cognitive impairment
NSAIDs compared to placebo for the prevention of dementia in people with MCI

























































































































































Anticipated absolute effects* (95% CI)Outcomes











Incidence of Alzheimer's dis-
ease









Adverse events – cardiovascu-
lar









Adverse events – gastrointesti-
nal


















Cognitive decline from baseline — — — — — Not
mea-
sured.
Activities of daily living
assessed with: BDRS
Study reported no differences between treatment groups in any of
the annual mean BDRS scores: BDRS (difference rofecoxib minus
placebo: year 1: no data available; year 2: 0.0, 95% CI –0.1 to 0.2; year






Health-related quality of life — — — — — Not
mea-
sured.
*The risk in the intervention group (and its 95% confidence interval) is based on the assumed risk in the comparison group and the relative effect of the intervention (and
its 95% CI).
BDRS: Blessed Dementia Rating Scale; CI: confidence interval; MCI: mild cognitive impairment; RCT: randomised controlled trial; RR: risk ratio.
GRADE Working Group grades of evidence
High certainty: we are very confident that the true effect lies close to that of the estimate of the effect.
Moderate certainty: we are moderately confident in the effect estimate: the true effect is likely to be close to the estimate of the effect, but there is a possibility that it is
substantially different.
Low certainty: our confidence in the effect estimate is limited: the true effect may be substantially different from the estimate of the effect.
Very low certainty: we have very little confidence in the effect estimate: the true effect is likely to be substantially different from the estimate of effect.
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B A C K G R O U N D
Description of the condition
Dementia is a term used to describe a variety of illnesses
which, although diverse in some respects, share common
clinical manifestations. These include pervasive impairment of
mental functioning, typically progressive memory loss, language
diDiculties, confusion and disorientation, and a decline in the
skills required to carry out activities of daily living (Coteilli
2012). Dementia may also involve behavioural and psychological
symptoms (Cohen-Mansfield 2000; Hoe 2005; Hoe 2006; Hoe 2007;
Hoe 2009). As dementia progresses, the increasing severity of
symptoms has a devastating eDect on the quality of life of the
aDected person and their carers (World Health Organization 2012).
Current estimates suggest there are 46.8 million people living
with dementia worldwide, and this is forecast to double every 20
years, reaching 74.7 million by 2030 and 131.5 million by 2050.
Approximately 9.9 million new cases present each year, equating
to one new case every 3.2 seconds. It is an expensive condition,
costing an estimated USD 818 billion worldwide in 2015 (Prince
2015). Given the seriousness of the impact of dementia on all
associated with the illness, its increasing prevalence, incidence and
burden of cost, the World Health Organization (WHO) has declared
dementia a world health priority (World Health Organization 2012).
There is global interest in research into ways of preventing or
delaying the onset of dementia.
Dementia: main subtypes and pathophysiology
Alzheimer's disease
Alzheimer's disease (AD) is considered the most common cause
of dementia, accounting for approximately 60% to 70% of all
cases. It has a prevalence of approximately 1% among people
aged 60 to 64 years, increasing to 40% in people aged 85
years and older (Brookmeyer 1998). AD is a neurodegenerative
disorder, characterised pathologically by amyloid plaques and
neurofibrillary tangles, and clinically by gradually progressive
cognitive decline, impairments in activities of daily living, and
behavioural and psychological symptoms (Gorelick 2010). As yet,
the precise mechanisms underlying the pathogenesis of AD are not
understood fully, but the hypothesis that inflammatory processes
are an integral part of the degeneration process was first posited
over 25 years ago (Rogers 1988; McGeer 1995; McGeer 1997).
Although dementia due to AD typically occurs in later life, there
is an extended preclinical stage that is characterised by distinct
neuropathological changes (Jack 2013). There are multiple risk
factors for AD beyond increasing age. The greatest genetic risk is
being a carrier of the APOE-ε4 allele of the gene for apolipoprotein
E. Other risk factors include history of mild cognitive impairment
(MCI), female sex, cardiovascular disease, obesity, diabetes mellitus
and low socioeconomic status, defined as low income and low level
of educational attainment (Barnes 2011; YaDe 2013; Walter 2014).
Vascular dementia
Vascular dementia (VaD) is the second most common type of
dementia. It is caused by cerebrovascular disease that directly
or indirectly damages brain structures important for cognitive
functioning (Roh 2014). Two factors are necessary for a diagnosis
of VaD, namely, a cognitive disorder evident on neuropsychological
testing, and a history of clinical stroke or cerebrovascular disease
detected by neuroimaging which is plausibly linked to the cognitive
disorder. VaD can be classified into 1. multi-infarct dementia,
2. strategic infarct dementia, 3. haemorrhagic dementia, 4.
subcortical ischaemic vascular dementia (SIVD) and 5. other forms
of VaD. The classic clinical picture of multi-infarct dementia is of
step-wise progression, where periods of stability are interrupted by
periods of rapid decline, fluctuation of symptoms and the presence
of focal neurological signs. However, SIVD is associated with
an insidious onset and gradual cognitive decline, mimicking the
course of AD (Chui 2007). Other forms of VaD have heterogeneous
causes, for example, vasculitis, cerebral amyloid angiopathy,
and hereditary diseases such as cerebral autosomal-dominant
arteriopathy with subcortical infarcts and leukoencephalopathy
(CADASIL) (Seo 2007; Park 2013; Patel 2013). Risk factors for VaD
include advancing age, male sex, history of cardiovascular disease
(myocardial infarction (MI), history of stroke or transient ischaemic
attack (TIA)), diabetes, obesity and smoking (McCullagh 2001).
Mixed dementia
It has become increasingly apparent that the boundaries between
the diDerent dementia subtypes are unclear and mixed forms
exist, particularly in older people. For example, one retrospective
clinico-pathological study of 1050 elderly people with a history of
dementia showed that of the total cohort, 62.9% had a clinical
diagnosis of probable or possible AD; 10% of VaD; 10.4% of non-
specific degenerative dementia; 9.5% of Parkinson's disease with
dementia; 1.5% of mixed dementia; and 5.7% of other dementias,
including frontotemporal dementia, Huntington's and Creutzfeldt-
Jakob diseases. Autopsy results, however, were significantly
diDerent: 86% had AD-related pathology but only 42.8% exhibited
'pure' AD while the remaining cases had mixed pathologies
(Jellinger 2006).
Description of the intervention
Aspirin and other non-steroidal anti-inflammatory drugs
Aspirin and other NSAIDs are indicated for the alleviation of
pain, inflammation and fever. Due to its anti-aggregation eDects
on platelets, aspirin is also indicated for the treatment and
prevention of cardiovascular disease. Aspirin is used at low doses
for cardiovascular prevention, whereas higher doses are used for
analgesic eDects.
Depending on the drug type, dose and duration of treatment,
aspirin and other NSAIDs are associated with a variety of adverse
events including serious cardiovascular events, hypertension,
gastrointestinal ulcers, acute renal failure and worsening of pre-
existing heart failure (Varga 2017).
Aspirin (a derivative of salicylate) was the original NSAID. It was
introduced onto the market in the late 19th century. Further NSAIDs
such as indomethacin and ibuprofen began to appear in the 1960s
(Conaghan 2012). However, it was not until the early 1970s that the
mechanism of action of aspirin (and by extension other NSAIDs) was
elucidated by John Vane (Vane 1971). His work identified it as an
inhibitor of the enzyme cyclo-oxygenase (COX). COX is responsible
for the first stage in the production of prostaglandins, local
hormones that have a range of physiological functions. Originally,
it was thought that all prostaglandin synthesis was initiated by a
single form of COX, but now at least two isoforms of COX are known
to exist, termed COX-1 and COX-2. COX-1 is present in small amounts
in most human tissues and acts as a 'housekeeping' enzyme,
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia (Review)
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involved in the regulation of normal physiological processes such
as the maintenance of gastric mucosal integrity, kidney function
and platelet aggregation. Conversely, COX-2 is undetectable in most
tissues under normal physiological circumstances and is selectively
upregulated aLer exposure to inflammatory mediators or trauma,
contributing to subsequent inflammatory responses and pain.
NSAIDs may be classified according to their selectivity for
COX-1 or COX-2, or both (Vane 1998). Early NSAIDs, including
aspirin, are non-selective COX inhibitors. It was hypothesised
that the therapeutic eDects (that is analgesic, antipyretic and
anti-inflammatory benefits) of all NSAIDs, including aspirin, were
due to inhibition of COX-2 and that unwanted adverse eDects
were due to inhibition of COX-1 (Vane 1998). Hence, it was
thought that if selective COX-2 inhibitors could be developed,
such compounds should have a similar eDicacy to non-selective
NSAIDs but with an improved safety profile as they would allow
the continued production of prostaglandins in locations such as the
gastrointestinal tract and thus limit adverse eDects such as mucosal
ulceration (Hawkey 1999). Several COX-2 selective inhibitors were
subsequently developed and marketed, including meloxicam,
nimesulide and the even more highly selective COX-2 inhibitors
known collectively as the 'coxibs'. However, some of these highly
selective compounds (namely rofecoxib and valdecoxib) have
subsequently been withdrawn from the market for safety reasons,
due to increased cardiovascular risk. Such compounds are also not
devoid of gastrointestinal problems, although the risk is less than
with non-selective NSAIDs (Patricio 2013).
How the intervention might work
In recent years, a well-defined neuro-inflammatory response has
been identified in AD (Kinney 2018). Considerable inflammation
is observed around the plaques and tangles that represent
the core histological features of the disease. COX enzymes and
prostaglandin pathways have thus come to attention as a possible
therapeutic target (McGeer 2000; Cudaback 2014; Kinney 2018).
The anti-inflammatory properties of aspirin and other NSAIDs may
interrupt or prevent inflammatory processes that are important
in pathogenesis, thus preventing the onset of AD (Etminan 2003).
Aspirin and other NSAIDs may also help to prevent VaD via their
anti-inflammatory and antiplatelet eDects (Devine 2003).
Besides their well-defined eDects on COX enzymes and hence
inflammatory pathways, it has also been suggested that certain
NSAIDs have an eDect on the formation of amyloid-beta (Aβ), the
major component of the plaques associated with AD. The synthesis
of Aβ requires the enzyme γ-secretase. Inhibitors of γ-secretase
have been investigated as possible disease-modifying drugs in AD
(Ozudogru 2012), with particular interest in selective drugs that
do not interfere with the processing of other substrates for the
enzyme (Crump 2013). Drugs with such properties are known as
g-secretase modulators (GSMs). However, the NSAIDs that possess
this GSM property (namely ibuprofen, flurbiprofen, indomethacin
and sulindac) are only weak inhibitors of the enzyme in vitro and
have low brain penetrability (Crump 2013), so the relevance of this
property in a clinical setting has been questioned.
Our understanding of dementia pathogenesis continues to evolve.
While early studies looking at inflammation had a specific
neuroinflammation focus, more recent evidence suggests that
systemic inflammation may also be a risk for development
of dementia (Cunningham 2015). If this is true then reducing
peripheral inflammation through anti-inflammatories may have
indirect cognitive benefits even if there is no direct neural eDect of
the drug.
Why it is important to do this review
Epidemiological studies report a lower prevalence of AD in
people who have regularly taken NSAIDs for the treatment of
rheumatological disorders, suggesting that NSAIDs may have a
protective eDect against AD (McGeer 1996; Stewart 1997; In't Veld
2001). Reviews of epidemiological studies also suggest that the
protective eDects may be influenced by the type and duration of
NSAID use. Long term use (defined as greater than 24 months) was
associated with greater risk reduction than short term use (defined
as less than 1 month) or intermediate term use (defined as 1 to 24
months) (Etminan 2003; Szekely 2004).
The eDectiveness of aspirin and other NSAIDs as treatments for
people with dementia due to AD and VaD has been evaluated in
Cochrane systematic reviews (Rands 2000; Jaturapatporn 2012).
The promising epidemiological evidence has not been reproduced
in prospective randomised clinical trials, whose results have been
largely disappointing.
As dementia, particularly AD and VaD, is such a major health
concern worldwide, and in the absence of any known preventive
or curative treatment, any intervention that can prevent or delay
the onset of dementia would have a major public health impact.
Therefore, we considered it important to assess in a systematic
review the strength of the evidence on the eDicacy and safety of
these drugs for the primary and secondary prevention of dementia.
We included as secondary prevention studies, trials in people with
MCI, which is considered a high-risk state, and in many cases
a precursor to dementia. This is the first Cochrane Review to
evaluate the eDects of aspirin and other NSAIDs for the prevention
of dementia in this population.
O B J E C T I V E S
To evaluate the eDectiveness and adverse eDects of aspirin and
other NSAIDs for the primary or secondary prevention of dementia.
M E T H O D S
Criteria for considering studies for this review
Types of studies
Randomised controlled trials (RCTs) and controlled clinical trials
(CCTs) in which aspirin and other NSAIDs were administered for the
primary or secondary prevention of dementia.
Types of participants
Participants were adults living in the community without a prior
diagnosis of dementia. Participants were identified as cognitively
healthy or with MCI. Participants identified as having MCI should
have had: 1. objective evidence of cognitive decline greater than
expected for age, and 2. no significant impairment in activities of
daily living.
Types of interventions
Eligible experimental interventions were 1. aspirin at any dose
or 2. other NSAIDs at any dose administered for the primary or
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secondary prevention of dementia. The control intervention was
placebo.
There is no consensus definition of primary and secondary
prevention in dementia. For this review, we defined primary
prevention as treating risk factors for the development of cognitive
decline with the intention of slowing or arresting the underlying
pathological process before any clinical features are evident. We
defined secondary prevention as treatment designed to slow or
arrest the pathological processes underlying cognitive decline
where some evidence of cognitive impairment may be detectable
but this is not yet suDicient to warrant a dementia label. In this
rubric, we included MCI.
Types of outcome measures
Primary outcomes
• Incidence of dementia, diagnosed according to standard
diagnostic criteria at the time the study was undertaken. We
included data on any dementia pathological subtype, but,
because NSAIDs may have specific eDects in the pathological
processes underlying AD, we favoured estimates of AD as our
primary outcome where reported.
• Adverse events, for example, cardiovascular (specifically MI and
stroke), gastrointestinal or renal events.
• Mortality.
Secondary outcomes
• Cognitive decline from baseline.
• Activities of daily living.
• Health-related quality of life.
Search methods for identification of studies
Electronic searches
The Information Specialist from the Cochrane Dementia
and Cognitive Improvement Group searched ALOIS
(www.medicine.ox.ac.uk/alois), the Cochrane Dementia and
Cognitive Improvement Group Specialized Register on 9 January
2020. The search terms were: aspirin OR "cyclooxygenase 2
inhibitor" OR aceclofenac OR acemetacin OR celecoxib OR
dexibruprofen OR dexketoprofen OR diclofenac sodium OR
diflunisal OR diflusinal OR etodolac OR etoricoxib OR fenbufen
OR fenoprofen OR flurbiprofen OR ibuprofen OR indometacin
OR indomethacin OR ketoprofen OR lumiracoxib OR mefenamic
OR meloxicam OR nabumetone OR naproxen OR nimesulide OR
"anti-inflammatory" OR piroxicam OR sulindac OR tenoxicam OR
tiaprofenic acid OR triamcinolone OR NSAIDS OR NSAID.
ALOIS is maintained by the Information Specialists for the
Cochrane Dementia and Cognitive Improvement Group and
contains studies in the areas of dementia prevention, dementia
treatment and cognitive enhancement in healthy people. The
studies are identified from the following. 
• Monthly searches of a number of major healthcare databases:
MEDLINE, Embase, CINAHL, PsycINFO and LILACS.
• Monthly searches of a number of trial registers: ISRCTN;
UMIN (Japan's Trial Register); WHO International Clinical
Trials Registry Platform portal (which covers ClinicalTrials.gov;
ISRCTN; the Chinese Clinical Trials Register; the German Clinical
Trials Register; the Iranian Registry of Clinical Trials; and the
Netherlands National Trials Register, plus others).
• Quarterly searches of  the Cochrane Central Register of
Controlled Trials (CENTRAL).
• Six-monthly searches of a number of grey literature sources: ISI
Web of Science Core Collection.
To view a list of all sources searched for by ALOIS, see  About
ALOIS  on the ALOIS website (www.medicine.ox.ac.uk/alois/
content/about-alois).
The Information Specialists ran additional separate searches in
many of the above sources to ensure that the search was as
comprehensive and most up-to-date as possible. The search
strategies used can be seen in Appendix 1.
Searching other resources
We reviewed citations of reference lists of included studies
identified through the search strategy for additional studies and
assessed their suitability for inclusion in the review.
Data collection and analysis
The methods that were undertaken in this review were designed
in accordance with recommendations described in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011).
Selection of studies
Two review authors (FJ and DD) independently screened all
titles and abstracts identified from searches to identify those
which might meet the inclusion criteria. We retrieved in full
text any papers identified as potentially relevant by at least
one review author. Two review authors (from BMcG, PP or
FJ) independently screened full-text articles for inclusion or
exclusion. Any disagreements were resolved by discussion or,
where necessary, we consulted a third review author (DD, TQ or
KM).
Data extraction and management
For included trials, two review authors (FJ and DD) independently
extracted study characteristics. Outcome data were extracted using
data extraction sheets designed by one review author (CTS) and
piloted by two review authors (CTS and FJ). Two of three review
authors (CTS, FJ and TQ) independently extracted outcome data.
Any discrepancies were resolved through discussion. All extracted
data was entered into Review Manager 5 by one review author
(FJ), and a second review author (CTS or TQ) checked the data for
accuracy (Review Manager 2014).
Assessment of risk of bias in included studies
Two of three review authors (FJ, DD or TQ) independently assessed
the methodological quality of all trials included in the review
using the Cochrane 'Risk of bias' tool as described in Chapter 8
of the Cochrane Handbook for Systematic Reviews of Interventions
(Higgins 2011). The domains assessed as potential sources of
bias were: sequence generation; allocation concealment; blinding
of participants, personnel and outcome assessors; incomplete
outcome data; selective outcome reporting; and other sources of
bias.
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Measures of treatment e9ect
Dichotomous data
For dichotomous data, where data were available, we presented
the results as a risk ratio (RR) with 95% confidence intervals (CI).
Continuous data
For continuous data, where data were available, we presented the
results using mean diDerences, with 95% CI. We planned to use
the standardised mean diDerences if studies measured the same
outcome but used diDerent measurement scales (Higgins 2011).
Time-to-event data
We planned to analyse time-to-event data as described by Tierney
(Tierney 2007), and detailed in Chapter 7, Section 7.7.6 of the
Cochrane Handbook for Systematic Reviews of Interventions (Higgins
2011).
Unit of analysis issues
Studies with multiple treatment groups
One of the included studies had two active treatment arms (one
selective COX-2 and one non-selective NSAID) (ADAPT Research
Group 2007/2006). We combined both arms to form a single 'NSAID'
group for primary analysis but also presented the results from each
arm of the trial separately.
Dealing with missing data
Where data were missing from included trials, we planned to
contact the trial lead author. For each of the included trials, where
data were available, we noted the level of attrition for each group,
per outcome or group of outcomes.
Assessment of heterogeneity
Initial assessment of heterogeneity was clinical, based on
populations, interventions and outcomes. Because we did
not conduct any meta-analyses, we did not assess statistical
heterogeneity between studies.
Assessment of reporting biases
This review included fewer than 10 trials so we did not formally
assess publication bias using funnel plots.
Data synthesis
We prespecified the following comparisons.
• Aspirin at any dose versus placebo.
• Other NSAIDs at any dose versus placebo.
There are theoretical reasons to believe that selective COX-2
inhibitors may diDer in their therapeutic and adverse eDects from
non-selective NSAIDs. Where selective and non-selective NSAIDs
were available, we planned to combine data in a primary analysis,
but also to present data separately.
Because of clinical diversity among the included trials, we did not
conduct any meta-analyses, but rather we described the results for
each of the included trials separately using a narrative summary
approach.
Summarising and interpreting results
For each comparison, we produced a narrative 'Summary of
Findings' table (Higgins 2011), using the GRADEpro Guideline
Development Tool (GDT) (GRADEpro GDT). Where data were
available, we summarised the certainty of the evidence for the
primary and secondary outcomes detailed in the Types of outcome
measures section.
Subgroup analysis and investigation of heterogeneity
We did not undertake any subgroup analyses to investigate
heterogeneity because of the small numbers of included studies.
Sensitivity analysis
We did not perform any sensitivity analyses.
R E S U L T S
Description of studies
Results of the search
The results of the search are presented in Figure 1. Electronic
searches retrieved 3627 citations, with four additional studies
identified through other sources, giving a total of 3631 references.
ALer the removal of duplicates, we screened the titles and abstracts
of 2211 studies. We obtained the full text for 25 papers. We excluded
21 papers for reasons described in the Characteristics of excluded
studies table.
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Figure 1.   Study flow diagram. RCT: randomised controlled trial.
 
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia (Review)









Cochrane Database of Systematic Reviews
Included studies
We included four RCTs with 23,187 participants (Thal 2005; ADAPT
Research Group 2007/2006; Small 2008; ASPREE 2018). For full
details, see Characteristics of included studies table.
Participants and setting
The Aspirin in Reducing Events in the Elderly (ASPREE) trial was
a primary prevention study conducted in Australia and the US
(ASPREE 2018). Participants (n = 19,114) were aged 70 years or older
(or 65 years of age or older among Hispanic or black people in
the USA) and free of dementia, chronic illness, or cardiovascular or
cerebrovascular diseases at recruitment.
The Alzheimer's Disease Anti-inflammatory Prevention Trial
(ADAPT) was a primary prevention trial conducted in six sites across
the USA (ADAPT Research Group 2007/2006). Participants (n = 2528)
were cognitively healthy volunteers, aged 70 years or more with a
family history of AD. Participants were deemed cognitively healthy
on the basis of predefined cut-oD scores on a battery of cognitive
tests.
Small 2008 was a secondary prevention trial conducted in a
university research institute in California (US). Participants (n =
88) were volunteers, aged 40 to 81 years, with mild self-reported
memory complaints but normal memory performance scores.
They were recruited from community physician referrals, media
coverage and advertising.
Thal 2005 was a secondary prevention study conducted across
46 study sites in the USA. Participants (n = 1457) were aged 65
years or older and had a clinical diagnosis of MCI. A diagnosis of
MCI was determined using several criteria including self-report and
informant report of memory decline in the previous year; a Mini-
Mental State Examination (MMSE) score of 24 or greater; a Clinical
Dementia Rating (CDR) global score of 0.5 with memory domain
score of 0.5 or greater; a Blessed Dementia Rating Scale (BDRS) total
score of 3.5 or less with no part 1 item score greater than 0.5; and
an Auditory Verbal Learning Test (AVLT) total score of 37 or less.
Interventions
ASPREE 2018 evaluated the eDicacy of low-dose aspirin for
extending a disability-free life over a five-year period. Participants
were randomly allocated to aspirin 100 mg or placebo once daily.
ALer an interim analysis, the trial was terminated at a median of 4.7
years of follow-up, just five months ahead of schedule.
ADAPT Research Group 2007/2006 evaluated the eDicacy and safety
of the selective COX-2 inhibitor, celecoxib, and the non-selective
NSAID, naproxen, for the primary prevention of AD. Participants
were assigned randomly to celecoxib 200 mg twice daily (BID)
or naproxen 220 mg BID or placebo BID. Initially this trial was
intended to last for seven years, but was ended prematurely
aLer increased cardiovascular risks associated with celecoxib were
observed in the Adenoma Prevention with Celecoxib (APC) trial
(Solomon 2005). Median follow-up times for participants were 733
days for celecoxib, 734 days for naproxen and 735 days for placebo.
Small 2008 studied the eDects of the selective COX-2 inhibitor,
celecoxib, on cognitive performance. Participants were assigned
randomly to a daily dose of celecoxib 200 mg or 400 mg or
placebo for a period of 18 months. Following the termination of the
ADAPT trial, for the reasons stated earlier in the text, this trial was
terminated at the same time (Small 2008). In the celecoxib group,
mean follow-up was 17.6 (standard deviation (SD) 5.3) months and
for the placebo group it was 18.1 (SD 4.7) months.
Thal 2005 studied the eDectiveness of rofecoxib, a COX-2 inhibitor,
in delaying conversion from MCI to dementia due to AD.
Participants were assigned randomly to rofecoxib 25 mg or placebo
once daily. This study was expected to run over four years.
However, the study was terminated in April 2003, 11 months earlier
than the planned termination date because Merck announced
the voluntary withdrawal of rofecoxib from the market following
reported association with increased cardiovascular risk in another
trial (Bresalier 2005). Median duration for study participation was
115 weeks in the rofecoxib group and 130 weeks in the placebo
group.
Outcomes measured in included trials that were relevant to this
review
The primary endpoint in the ASPREE trial was a composite of
dementia, physical disability and death (ASPREE 2018). Dementia
was also reported as a secondary endpoint, diagnosed according to
the Diagnostic and Statistical Manual of Mental Disorders-IV criteria
(DSM-IV) (APA 1994).
Incidence of AD was the primary outcome in ADAPT (ADAPT
Research Group 2007/2006), diagnosed using the National Institute
of Neurological and Communicative Disorders and Stroke –
Alzheimer's Disease and Related Disorders Association Criteria
(NINCDS-ADRDA) (McKhann 1984). The trial also included incidence
of all-cause dementia as a secondary outcome, which was
diagnosed according to DSM-IV criteria (APA 1994).
Incidence of AD was the primary outcome in Thal 2005, diagnosed
according to NINCDS-ADRDA criteria (McKhann 1984).
All trials reported adverse events (Thal 2005; ADAPT Research
Group 2007/2006; Small 2008; ASPREE 2018).
Three trials reported mortality (Thal 2005; ADAPT Research Group
2007/2006; ASPREE 2018).
Two trials reported cognitive decline from baseline (ADAPT
Research Group 2007/2006; Small 2008). Small 2008 measured
a change in cognition from baseline across six cognitive
domains: psychomotor speed, visuospatial functioning, executive
functioning, learning, delayed recall and language/semantic
memory. Thal 2005 reported annualised changes in cognition over
a four-year period; data were presented as change per annum for
each year and it was not possible to extrapolate a summary of total
cognitive change from baseline.
ASPREE 2018 measured rates of MCI as an outcome, but results for
this outcome are not published yet.
Incidence of MCI and AD prodromes were a secondary outcome in
ADAPT (ADAPT Research Group 2007/2006). We regarded incident
MCI as aligned with our outcome of cognitive decline because
it represents a state of change from baseline normal cognition
that is not suDicient to make a diagnosis of dementia. The
trial administered the following battery of cognitive tests at
baseline and at yearly follow-ups: the Modified Mini-Mental Sate
Examination (3MS-E) (Teng 1987), the Hopkins Verbal Learning
Test – Revised (HVLT-R) (Brandt 1991), informant-based Dementia
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Severity Rating Scale (DSRS) (Clark 1996), Digit Span Test
(Richardson 2007), Generative Verbal Fluency, narratives from
the Rivermead Behavioural Memory test (Wilson 1989), Brief
Visuospatial Test-Revised (Benedict 1996), and self-rating of
memory functions (Squire 1979). It also included the Geriatric
Depression Scale (GDS) (Yesavage 1983).
Two trials reported activities of daily living (Thal 2005; ASPREE
2018). Activities of daily living were measured in ASPREE 2018 using
the Katz Index of Independence in Activities of Daily Living tool
(Katz 1970). Thal 2005 measured activities of daily living using
the BDRS (Morris 1988) at baseline, 24, 36 and 48 months, or at
discontinuation from the study.
None of the trials reported health-related quality of life.
Excluded studies
We excluded 22 studies (see Characteristics of excluded studies
table).
Risk of bias in included studies
We summarised the 'Risk of bias' results in Figure 2 and Figure 3.
See Characteristics of included studies table.
 
Figure 2.   Risk of bias graph: review authors' judgements about each risk of bias item presented as percentages
across all included studies.
Sequence generation
Allocation concealment
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ADAPT Research Group 2007/2006 + + + + + + +
ASPREE 2018 + + + + + + +
Small 2008 + ? ? ? - + +
Thal 2005 + ? + + + + +
 
Allocation
We judged all four included trials at low risk of bias in relation
to sequence generation. We judged two trials at low risk of bias
for allocation concealment (ADAPT Research Group 2007/2006;
ASPREE 2018), and two trials at unclear risk because of lack of detail
about allocation concealment in the reports (Thal 2005; Small
2008).
Blinding
We judged three trials at low risk of performance bias (blinding
of participants and personnel) and low risk of detection bias
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(blinding of outcome assessors) (Thal 2005; ADAPT Research Group
2007/2006; ASPREE 2018). We judged one trial at unclear risk of
performance and detection bias because insuDicient details were
available to make a clear judgement (Small 2008).
Incomplete outcome data
We judged three trials at low risk of attrition bias (Thal 2005; ADAPT
Research Group 2007/2006; ASPREE 2018). We judged one study
at high risk of attrition bias as there was substantial attrition not
accounted for in the analyses (Small 2008). One study reported
per-protocol analysis excluding participants with known cognitive
syndromes who were incorrectly enrolled into the trial (ADAPT
Research Group 2007/2006). For the outcomes of interest to this
review, we extracted and presented these per-protocol data. For
each included study, details pertaining to loss to follow-up are
presented in the Characteristics of included studies table.
Selective reporting
We judged all four trials at low risk of reporting bias because
they reported all the outcome measures detailed in the methods
sections of papers. Our assessment of reporting bias is in keeping
with that described in our original protocol (Jordan 2015). We
recognise that assessment of reporting bias has evolved and
usual practice now would be to compare the study protocol to
the published papers. Only two included studies had protocols
available in the public domain (ADAPT Research Group 2007/2006;
ASPREE 2018).
Other potential sources of bias
We did not identify any other high risks of bias. Two studies were
funded by the pharmaceutical industry; their source of funding was
reported in the trial publications and we did not judge this to pose
a risk of bias (Thal 2005; ADAPT Research Group 2007/2006).
E9ects of interventions
See: Summary of findings 1 Aspirin compared to placebo for
prevention of dementia; Summary of findings 2 Other NSAIDs
compared to placebo for the prevention of dementia in cognitively
healthy older adults; Summary of findings 3 NSAIDs (celecoxib)
compared to placebo for the delay of cognitive decline in older
people with age-related memory loss; Summary of findings 4
NSAIDs (rofecoxib) for the prevention of dementia in people with
mild cognitive impairment
1. Aspirin at any dose compared with placebo
See Summary of findings 1.
One trial compared aspirin versus placebo (ASPREE 2018).
Cognitively healthy older adults
Incidence of dementia: 575/19,114 (3%) participants had
dementia across both treatment groups (283/9525 (3%) in the
aspirin group and 292/9589 (3%) in the placebo group). There was
no diDerence in incidence of dementia between treatment groups
(RR 0.98, 95% CI 0.83 to 1.15; high-certainty evidence; Analysis 1.1).
Adverse events: at follow-up, 626/19,114 (3.3%) participants had
experienced a major haemorrhagic event. The incidence of major
bleeding was higher in the aspirin group (361/9525 (3.8%) than the
placebo group (265/9589 (2.8%) (RR 1.37, 95% CI 1.17 to 1.60; high-
certainty evidence; Analysis 1.2).
Mortality: at follow-up, 1050/19,114 (5.5%) participants had died.
Mortality was slightly higher in participants allocated aspirin
(558/9525 (5.8%) than those allocated placebo (494/9589 (5%) (RR
1.14, 95% CI 1.01 to 1.28; high-certainty evidence; Analysis 1.3).
Cognitive decline from baseline: the trial measure MCI but results
are not yet published.
Activities of daily living: at follow-up, 412/19,114 (2.2%)
participants experienced impairment in activities of daily living
(188/9525 (2%) in the aspirin group and 224/9589 (2.3%) in the
placebo group). There was no clear evidence of a diDerence in
activities of daily living between groups (RR 0.84, 95% CI 0.70 to
1.02; high-certainty evidence; Analysis 1.4).
Health-related quality of life: the trial did not assess health-
related quality of life.
2. Other NSAIDs at any dose compared with placebo
See Summary of findings 2; Summary of findings 3; Summary of
findings 4.
Three trials compared other NSAIDs versus placebo (Thal 2005;
ADAPT Research Group 2007/2006; Small 2008). We judged that
outcome data from the three trials could not be combined because
of clinically heterogeneous participants (participants in one trial
were cognitively healthy, participants in another trial had age-
related memory loss and participants in the other trial had MCI).
Pooling of adverse events was not possible because of the diversity
in the type of reported events. Findings for each of the outcomes
reported in the individual trials and relevant to this review are
presented separately.
Cognitively healthy older adults with a family history of
Alzheimer's disease (ADAPT 2007/2006)
ADAPT Research Group 2007/2006 compared celecoxib, naproxen
and placebo.
Incidence of dementia: the focus of this study was the primary
prevention of AD. Of the total number of trial participants,
2125/2528 participants contributed to the analyses of cognitive
outcomes. A total of 32/2125 (1.5%) participants were diagnosed
with AD across all treatment groups (11/619 (1.8%) in celecoxib
group, 12/598 (2%) in naproxen groups and 9/908 (1%) in placebo
group). We combined findings from both NSAID treatment arms and
found no evidence of a diDerence in the incidence of AD between
participants allocated NSAIDs and those allocated placebo (RR
1.91, 95% CI 0.89 to 4.10; moderate-certainty evidence; Analysis
2.1). Similarly, there was no evidence of a diDerence in the incidence
of AD between participants allocated celecoxib and those allocated
placebo (RR 1.79, 95% CI 0.75 to 4.30; 1527 participants ; moderate-
certainty evidence; Analysis 2.1), or between participants allocated
naproxen and those allocated placebo (RR 2.02, 95% CI 0.86
to 4.78; 1506 participants; moderate-certainty evidence; Analysis
2.1). Analysis of the secondary outcome of all-cause dementia,
excluding seven participants with prevalent dementia incorrectly
enrolled into the trial, suggests a diDerence in incidence of all-
cause dementia between participants allocated NSAIDs and those
allocated placebo in favour of placebo (RR 2.45, 95% CI 1.05 to 5.68;
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2118 participants; low-certainty evidence; Analysis 2.2). Results
from the individual NSAIDs groups were compatible with little or no
diDerence between groups (RR 2.50, 0.99 to 6.32; 1523 participants;
low-certainty evidence; Analysis 2.2 ) and naproxen (RR 2.39, 95%
CI 0.93 to 6.12; 1499 participants; low-certainty evidence; Analysis
2.2).
Adverse events: the trial reported cardiovascular adverse events.
A total of 2528/2500 (98.9%) participants had follow-up for
non-fatal events. Non-fatal cardiovascular events measured were
MI, stroke, congestive heart failure (CHF), TIA and initiation of
antihypertensive treatments. Results for each of the reported
adverse events are presented below.
• MI: 34/2500 participants experienced a non-fatal MI across
all treatment groups (8/717 (1.1%) in celecoxib group, 13/713
(1.8%) in naproxen group and 13/1070 (1.2%) in placebo group).
Combining findings from both NSAID groups, we found no
evidence of a diDerence in incidence of MI in participants
allocated NSAIDs compared with those allocated placebo (RR
1.21, 95% CI 0.61 to 2.40; 2500 participants; moderate-certainty
evidence; Analysis 2.3). This was true of both NSAIDs individually
(celecoxib: RR 0.92, 95% CI 0.38 to 2.20; 1787 participants;
moderate-certainty evidence; Analysis 2.3), naproxen: RR 1.50,
95% CI 0.70 to 3.22; 1783 participants; moderate-certainty
evidence; Analysis 2.3).
• Stroke: 24/2500 participants experienced a stroke across all
treatment groups (7/717 (1%) in celecoxib group, 10/713 (1.4%)
in naproxen group and 7/1070 (0.6%) in placebo group).
Combining findings from both NSAID groups, we found no
evidence of a diDerence in incidence of stroke in participants
allocated NSAIDs compared with those allocated placebo
(RR 1.82, 95% CI 0.76 to 4.37; 2500 participants; moderate-
certainty evidence; Analysis 2.4). This was also true of the
individual NSAIDs (celecoxib: RR 1.49, 95% CI 0.53 to 4.24;
1787 participants; moderate-certainty evidence; Analysis 2.4,
naproxen: RR 2.14, 95% CI 0.82 to 5.61; 1783 participants;
moderate-certainty evidence; Analysis 2.4).
• CHF: 18/2500 participants experienced CHF across all treatment
groups (3/717 (0.4%) in celecoxib group, 8/713 (1.1%) in
naproxen group and 7/1070 (0.6%) in placebo group).
Combining findings from both NSAID groups, we found no
evidence of a diDerence in incidence of CHF in participants
allocated NSAIDs compared with those allocated placebo
(RR 1.18, 95% CI 0.46 to 3.02; 2500 participants; moderate-
certainty evidence; Analysis 2.5). This was also true of the
individual NSAIDs (celecoxib: RR 0.64, 95% CI 0.17 to 2.47;
1787 participants; moderate-certainty evidence; Analysis 2.5,
naproxen: RR 1.72, 95% CI 0.62 to 4.71; 1783 participants;
moderate-certainty evidence; Analysis 2.5).
• TIA: 27/2500 participants experienced TIA across all treatment
groups (8/717 (1.1%) in celecoxib group, 9/713 (1.2%) in
naproxen group and 10/1070 (0.9%) in placebo group).
Combining findings from both NSAID groups, we found no
evidence of a diDerence in incidence of TIA in participants
allocated NSAIDs compared with those allocated placebo
(RR 1.27, 95% CI 0.58 to 2.77; 2500 participants; moderate-
certainty evidence; Analysis 2.6). This was also true of the
individual NSAIDs (celecoxib: RR 1.19, 95% CI 0.47 to 3.01;
1787 participants; moderate-certainty evidence; Analysis 2.6,
naproxen: RR 1.35, 95% CI 0.55 to 3.31; 1783 participants;
moderate-certainty evidence; Analysis 2.6).
• Initiation of antihypertensive therapy: we had not prespecified
this as an outcome of interest, but, because hypertension is a
risk factor for dementia, we considered that it was important
to include this reported adverse event. The proportion of
participants receiving antihypertensive treatment was well-
balanced across all treatment groups at baseline (39.4% in
celecoxib group, 39.2% in naproxen group and 40.5% in placebo
group). Across all treatment groups, 471/1521 participants
initiated treatment for hypertension (160/440 (36%) in celecoxib
group, 147/437 (34%) in naproxen group and 164/644 (25%) in
placebo group). Combining findings from both NSAID groups,
we found that a higher proportion of participants allocated
NSAIDs were started on antihypertensive treatment compared
with those allocated placebo (RR 1.37, 95% CI 1.17 to 1.61; 1521
participants; moderate-certainty evidence; Analysis 2.7). This
was also true of the individual NSAIDs (celecoxib: RR 1.43, 95%
CI 1.19 to 1.71; 1084 participants; moderate-certainty evidence;
Analysis 2.7, naproxen: RR 1.32, 95% CI 1.10 to 1.59; 1081
participants; moderate-certainty evidence; Analysis 2.7).
Mortality: all 2528 participants contributed to analyses of
mortality. FiLy-one participants died across all treatment groups
(17/726 (2.3%) in celecoxib group, 16/719 (2.2%) in naproxen group
and 18/1083 (1.7%) in placebo group). Combining findings from
both NSAID groups, we found no evidence of a diDerence in
incidence of mortality in participants allocated NSAIDs compared
with those allocated placebo (RR 1.37, 95% CI 0.78 to 2.43; 2528
participants; moderate-certainty evidence; Analysis 2.8). This was
true of both NSAIDs individually (celecoxib: RR 1.41, 95% CI 0.73 to
2.72; 1809 participants; moderate-certainty evidence; Analysis 2.8,
naproxen: RR 1.34, 95% CI 0.69 to 2.61; 1802 participants; moderate-
certainty evidence; Analysis 2.8).
Cognitive decline from baseline: a diagnosis of MCI was a
secondary endpoint in this trial. Participants were supposed to be
healthy adults at baseline but aLer randomisation 53 participants
were diagnosed with cognitive impairment so the analyses for
incidence of MCI, which we accepted as evidence of a change in
cognition from baseline. excluded those 53 participants. At the
end of the study, a total of 49 participants were diagnosed with
MCI (16/605 (2.6%) in celecoxib group, 15/582 (2.6%) in naproxen
group and 18/885 (2%) in placebo group). Combining findings from
both NSAID groups, we found no evidence of a diDerence in the
incidence of MCI between participants allocated NSAIDs and those
allocated placebo (RR 1.28, 95% CI 0.72 to 2.28; 2072 participants;
low-certainty evidence; Analysis 2.9). There was no evidence of
a diDerence from placebo for either of the NSAIDs individually
(celecoxib: RR 1.30, 95% CI 0.67 to 2.53; 1490 participants; low-
certainty evidence; Analysis 2.9, naproxen: RR 1.27, 95% CI 0.64 to
2.49; 1467 participants; low-certainty evidence; Analysis 2.9) .
Activities of daily living: the trial did not report activities of daily
living.
Health-related quality of life: the trial did not report health-
related quality of life.
Adults with age-related memory loss (Small 2008)
Small 2008 compared celecoxib and placebo.
Incidence of dementia: the trial did not report the incidence of
dementia.
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Adverse events: of the 88 participants randomised, only 40
participants contributed to the analyses of adverse events. Thirteen
(59%) participants allocated celecoxib and four (22%) participants
allocated placebo experienced adverse gastrointestinal events,
which included gastritis, nausea and abdominal pain (RR 2.66, 95%
CI 1.05 to 6.75; 40 participants; low-certainty evidence; Analysis
3.1).
Mortality: the trial did not report mortality.
Cognitive decline from baseline: our analyses, undertaken at
the individual cognitive test level within each of the six cognitive
domains, found no evidence of a diDerence in cognition between
participants allocated celecoxib and those allocated placebo (40
participants; low-certainty evidence for all cognitive measures
across all six cognitive domains). The analyses for individual
cognitive tests measured within each of the six cognitive domains
are presented in Summary of findings 3. Contrary to our findings,
the study reported significant between-group diDerences in the
domains of executive functioning and language/semantic memory
in favour of celecoxib. However, they used a diDerent method of
analysis. Within each domain, the raw data from the individual
cognitive tests were converted to Z scores and the mean Z scores
for each domain were used to compare groups.
Activities of daily living: the trial did not report activities of daily
living.
Health-related quality of life: the trial did not report health-
related quality of life.
Older adults with mild cognitive impairment (Thal 2005)
Thal 2005 compared rofecoxib versus placebo.
Incidence of dementia: 189 participants with MCI were diagnosed
with AD over the period of the trial (107/725 (14.8%) in rofecoxib
group and 82/732 (11.2%) in placebo group). Participants allocated
to rofecoxib were more likely to convert to AD than those allocated
placebo, although the result was imprecise and also compatible
with little or no diDerence between the groups (RR 1.32, 95% CI 1.01
to 1.72; 1457 participants; moderate-certainty evidence; Analysis
4.1). The study reported an estimated annual rate of AD diagnosis
of 6.4% in the rofecoxib group compared with 4.5% in the placebo
group.
Adverse events: the trial reported the total number of
cardiovascular and gastrointestinal adverse events. There were
74 cardiovascular adverse events across both treatment groups
(38/725 (5.2%) in rofecoxib group and 36/732 (4.9%) in placebo
group). There was no evidence of a diDerence in cardiovascular
adverse events between treatment groups (RR 1.07, 95% CI 0.68
to 1.66; 1457 participants; moderate-certainty evidence; Analysis
4.2). There were 18 confirmed upper gastrointestinal ulcers, bleeds
or perforations across both treatment groups (14/725 (1.9%)
in rofecoxib group and 4/732 (0.55%) in placebo group). This
represents a higher rate of gastrointestinal adverse events in
participants allocated rofecoxib than in those allocated placebo (RR
3.53, 95% CI 1.17 to 10.68; 1457 participants; moderate-certainty
evidence; Analysis 4.2).
Mortality: there were 39 deaths across both treatment groups
(24/723 (3.3%) in rofecoxib group and 15/728 (2.1%) in placebo
group), with no evidence of a diDerence in mortality between
treatment groups (RR 1.62, 95% CI 0.85 to 3.05; 1457 participants;
moderate-certainty evidence; Analysis 4.3).
Cognitive decline from baseline: the trial did not report cognitive
decline from baseline. Data were presented for annual between-
group diDerences in mean scores on cognitive tests including the
Story Recall Test (SRT) – Summed Recall, SRT-Delayed Recall,
Alzheimer's Disease Assessment Scale – Cognitive Subscale (ADAS-
Cog) and the MMSE. For each test, there was no evidence of an
annual between-group diDerence.
Activities of daily living: data were presented for change in
activities of daily living score for each year. Data for this outcome
were not reported in a way suitable for our planned analyses so we
reported the findings for this outcome directly from the study. The
study reported no diDerences between treatment groups in any of
the annual mean BDRS scores (BDRS: diDerence rofecoxib minus
placebo: year 1: no data available; year 2: 0.0, 95% CI –0.1 to 0.2;
year 3: 0.1, 95% CI –0.1 to 0.3; year 4: 0.1, 95% CI –0.1 to 0.4; 1457
participants; moderate-certainty evidence; data for this outcome
are presented in Summary of findings 4).
Health-related quality of life: the trial did not report health-
related quality of life.
D I S C U S S I O N
Summary of main results
The objective of this review was to evaluate the eDectiveness and
safety of aspirin and other NSAIDs for the primary and secondary
prevention of dementia.
For the comparison of aspirin with placebo, we included only
one trial (ASPREE 2018). This trial evaluated the eDects of low-
dose aspirin for extending disability-free survival – an endpoint
that combined dementia, all-cause death and physical disability
– among healthy older people. There was no evidence of a
diDerence between groups in rates of dementia and no diDerence
in related outcomes such as functional status (i.e. ability to perform
activities of daily living independently). However, participants
allocated to aspirin had higher rates of mortality and higher rates of
major haemorrhagic events compared with participants allocated
placebo.
For the second comparison of other NSAIDs with placebo, we
included three trials with 4073 participants. Due to heterogeneity
between studies, we assessed each study separately.
One primary prevention trial evaluated the eDectiveness of the
selective COX-2 inhibitor celecoxib and the non-selective COX
inhibitor naproxen in preventing dementia in cognitively healthy
adults aged 70 years and older who were at risk of dementia by
virtue of family history (ADAPT Research Group 2007/2006). The
trial was supposed to run for seven years but was suspended aLer
two years due to concerns around safety. Incidence of AD was the
primary outcome in this trial. There was no evidence of a diDerence
in the incidence of AD between treatment groups. The trial
reported all-cause dementia, excluding participants with prevalent
dementia, which indicated a potentially higher incidence of all-
cause dementia in those prescribed NSAIDs. There was no evidence
of a diDerence in cardiovascular adverse events and mortality
between the groups. The trial did not report our other safety
outcomes of interest, gastrointestinal bleeding and renal events.
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Initiation of antihypertensives, a proxy for incident hypertension,
was assessed and was higher in participants receiving NSAIDs. This
trial measured incidence of MCI, which we included as a proxy
for our outcome of cognitive decline from baseline; there was no
diDerence in this outcome between groups. The trial did not report
activities of daily living and health-related quality of life.
The second included trial for this comparison was a secondary
prevention trial evaluating the eDectiveness of the selective COX-2
inhibitor celecoxib 200 mg or 400 mg once daily in delaying
cognitive decline in adults with age-related memory loss (Small
2008). This trial was planned to run for 18 months but was
terminated early due to safety concerns. Gastrointestinal adverse
events were more common in the celecoxib group. Our analysis
found no diDerence in cognition between groups. However, the
trial authors reported significant between-group diDerences in
executive functioning and language/semantic memory in favour of
celecoxib; this may be explained by the diDerent methods used to
analyse data, making a direct comparison of findings diDicult.
The third included trial for this comparison was a secondary
prevention trial that evaluated the eDectiveness of the selective
COX-2 inhibitor rofecoxib once daily in delaying a diagnosis of AD
in participants with MCI (Thal 2005). The trial was planned to run
for four years but was suspended early due to safety concerns.
Results indicated that participants with MCI allocated rofecoxib had
a higher conversion to AD compared with participants allocated
placebo. There was no diDerence in cardiovascular adverse events
between treatment groups but gastrointestinal adverse events
were more common in the rofecoxib group. There was no evidence
of a diDerence in mortality, cognitive decline from baseline and
activities of daily living between treatment groups. The trial did not
report health-related quality of life.
Overall completeness and applicability of evidence
This review sought to establish the evidence to support the use of
aspirin and other NSAIDs for the primary and secondary prevention
of dementia. The dose of aspirin used in ASPREE 2018 was low. It
is plausible that higher doses of aspirin may be needed to have
suDicient anti-inflammatory eDects but, given the adverse events
demonstrated with low-dose aspirin in this trial, future evaluations
of higher doses of aspirin for dementia prevention may be limited
by dose-dependent adverse eDects.
Three NSAIDs were included in the review: celecoxib, rofecoxib
(both COX-2 inhibitors) and naproxen (a non-selective COX
inhibitor), thus we had relevant data on all drug classes within
our 'anti-inflammatory' rubric. It seems likely that the results
demonstrated in the two included trials indicate a class eDect for
NSAIDs.
Our primary outcomes of interest were incidence of dementia,
adverse events and mortality. Three of the included studies
had robust measures of dementia (Thal 2005; ADAPT Research
Group 2007/2006; ASPREE 2018). In the two NSAID studies that
measured dementia (ADAPT Research Group 2007/2006; ASPREE
2018), we favoured data on incident AD over undiDerentiated
dementia, as this is the dementia subtype that was hypothesised
to be most amenable to modification through use of NSAIDs.
Although all included papers reported adverse events, there was
inconsistency in the data reported. NSAIDS oLen have adverse
cardiovascular, gastrointestinal and renal eDects, and it is plausible
that important adverse event data were not included. Other
important prespecified outcomes, such as health-related quality of
life was not included in the available studies.
Quality of the evidence
This review included four trials. A meta-analysis of data was not
possible for either comparison due to clinical heterogeneity in the
populations studied; the interventions tested and the outcomes
reported. All four trials were placebo-controlled RCTs and sample
sizes in three of the included trial were large (Thal 2005; ADAPT
Research Group 2007/2006; ASPREE 2018). One trial had a small
sample size (Small 2008).
For the comparison of aspirin with placebo, ASPREE 2018 was
a well-designed trial and the certainty of the evidence for each
outcome was high. For the comparison of other NSAIDs compared
with placebo, in two of the included trials the certainty of
the evidence for each of the reported outcomes was moderate,
downgraded by one level due to imprecision because event
rates in both trials were low (Thal 2005; ADAPT Research Group
2007/2006). The certainty of the evidence in one NSAID trial was
low, downgraded two levels due to imprecision as event rates were
low and there was a risk of bias associated with on-treatment
analyses (Small 2008). Loss to follow-up varied across the included
trials. Reasons for loss to follow-up were provided in the individual
trial reports and seemed unlikely to cause a systematic bias. All of
the included trials were stopped early for safety rather than eDicacy
reasons, so for this reason the certainty of the evidence was not
downgraded further.
Potential biases in the review process
We believe that in adhering to the recommended Cochrane search
and review methods, we have identified all data of interest to the
review question. We recognise that aspects of study inclusion are
open to debate. Our interest was dementia prevention and so we
did not include studies of prevalent dementia. We opted to include
MCI, as this can be considered a high-risk state for future dementia
and MCI is not included in other Cochrane Reviews of NSAIDs.
Although our original remit was dementia prevention, we favoured
outcomes relevant to AD rather than all-cause (undiDerentiated)
dementia where both were reported.
Agreements and disagreements with other studies or
reviews
Much of the existing evidence to support the use of aspirin and
other NSAIDs in the primary and secondary prevention of dementia
stems from epidemiological studies. A systematic review and meta-
analysis of these observational studies (Etminan 2003), included
six cohort studies (13,211 participants) and three case-control
studies (1443 participants). Contrary to findings from this review
of trial evidence, the observational study review reported that
aspirin and other NSAIDs lower the risk of AD, particularly with
long-term use (defined as greater than 24 months). One updated
systematic review and meta-analysis included both observational
studies and RCTs evaluating NSAID use and the incidence of
dementia (Wang 2015). It reported that findings from observational
studies suggested that NSAIDs use was associated with a significant
reduction in the risk of AD. The diDerences between these
observational studies and the trial results in our review emphasises
the danger of making causal inferences based on non-randomised
data.
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We found one trial that looked at aspirin for vascular disease
that was relevant to our review question but did not contain
our outcomes of interest (Price 2008). In a post-hoc study of
a subgroup of participants, the research team administered a
neuropsychological battery at one of the follow-up visits. This
outcome does not represent incident dementia as there was no
diagnostic formulation and does not represent 'cognitive decline
from baseline' as only one assessment was made, albeit one
may assume that participants were cognitively healthy at time of
randomisation. Accepting these caveats, the results of this trial
agree with the results from the trials included in this review in that
aspirin showed no evidence of a beneficial cognitive eDect.
A U T H O R S '   C O N C L U S I O N S
Implications for practice
The available evidence does not support the use of aspirin,
celecoxib, naproxen or rofecoxib for the primary or secondary
prevention of dementia, taken at the doses and for the periods
of time detailed in this review. Aspirin did not demonstrate a
protective eDect but was associated with a higher rate of adverse
events. The consistency of results across the various non-steroidal
anti-inflammatory drugs (NSAIDs) would suggest that this is a class
eDect and our review findings probably apply to all NSAIDs. Similar
to the aspirin study, NSAID use demonstrated a high rate of adverse
events; this is in keeping with data from observational studies
where chronic exposure to NSAIDs is a common cause of iatrogenic
harm (García Rodríguez 2016).
Implications for research
Low-dose aspirin use demonstrated no protective eDect but was
associated with significant rates of adverse events. For this reason,
it seems unlikely that there should be further trials of low-dose
aspirin for dementia prevention. If future studies of NSAIDs for
dementia prevention are planned, then these will need to take
account of the safety concerns arising from the studies included in
this review and from other NSAID trials. The results of this review do
not mean that there is no potential for anti-inflammatory drugs to
modify dementia risk. However, drugs with less potential to cause
adverse events would be needed for future studies.
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C H A R A C T E R I S T I C S   O F   S T U D I E S
Characteristics of included studies [ordered by study ID]
 
Study characteristics
Methods Study design: RCT.
Data collection time points: cognitive screening undertaken at baseline and once a year for trial pe-
riod. Recruitment for trial started in March 2001. Initially, trial planned to last 7 years but treatments
were suspended in December 2004 after there were increased cardiovascular risks with celecoxib in the
Adenoma Prevention with Celecoxib (APC) trial.
Participants Setting: 6 sites across the USA.
Inclusion criteria: aged ≥ 70 years with family history of ≥ 1 first-degree relative with Alzheimer-like de-
mentia. A suitable informant was available to provide information on the cognitive status of the partici-
pant and to assist with monitoring of trial medications, if needed. Sufficient fluency in written and spo-
ken English to participate in study visits and neuropsychological testing. Willingness to limit use of the
following for duration of study: vitamin E (at doses > 400 IU daily), non-aspirin NSAIDs, histamine H2 re-
ceptor antagonists (e.g. cimetidine), corticosteroids, anti-inflammatory or analgesic doses of aspirin
(> 81 mg daily) and Ginkgo biloba extracts. Ability and intention to participate in regular study visits, in
the opinion of the study physician. Ability to provide informed consent.
Exclusion criteria: history of peptic ulcer disease with bleeding or obstruction. Clinically significant
liver or kidney disease. History of hypersensitivity to aspirin, ibuprofen, celecoxib, naproxen or other
NSAIDs. Use of anticoagulant medication. Cognitive impairment or dementia. Current alcohol abuse or
dependence.
Participants randomised: total 2528, 726 allocated celecoxib, 719 allocated naproxen and 1083 allo-
cated placebo. Of the total number of participants, 45.9% were women and 54.1% were men.
ADAPT Research Group 2007/2006 
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Interventions Intervention: celecoxib 200 mg BID or naproxen 220 mg BID.
Control: matching placebo.
Median follow-up times: 733 days for celecoxib, 734 days for naproxen and 734.5 days for placebo.
Outcomes Outcome relevant to this review
• Diagnosis of AD, diagnosed according to NINCDS-ADRDA criteria.
• Incidence of all-cause dementia diagnosed according to DSM-IV criteria.
• Cardiovascular events, i.e. non-fatal MI, stroke, CHF, TIA and initiation of antihypertensive treatments.
• Mortality.
• Diagnosis of MCI or AD prodromes (compatible with our outcome of cognitive decline from baseline),
assessed using a battery of cognitive tests, i.e. Brief Visuospatial Memory Test – Revised; generative
verbal fluency; Hopkins Verbal Learning Test – Revised; Rivermead Behavioral Memory Test and a
modified version of the MMSE (3MS-E).
Identification Authors name: CG Lyketsos
Institution: John Hopkins School of Medicine
E-mail: kostas@jhmi.edu




Bias Authors' judgement Support for judgement
Sequence generation Low risk Quote: "The randomisation sequence was generated by the trial's coordinat-
ing centre in permuted blocks stratified by three age groups (ages 70–74, ages
75–79, and ages 80+) and the six field sites, with an assignment ratio of 1:1:1.5.
Randomization was implemented via computer systems distributed to each
of the six sites. The sequence of bin assignments was concealed from site per-
sonnel via encoding and password protection of the randomisation files. Be-
fore randomizations, site personnel were required to enter baseline data. The
ADAPT computer system confirmed eligibility before releasing the bin assign-
ment" (pg. 1801).
Allocation concealment Low risk Quote: "using a distributed computerized system that released treatment as-





Low risk Judgement comment: treatments were administered using a double-blind
method. Blinding was accomplished using placebos matching the celecoxib
and naproxen treatments (without active ingredients). Treatment by study
personnel during the trial remained blinded to assignment. The blinding for
participants and study personnel remained in place until June 2007, when it
was lifted via mailings to study participants revealing their assignment.
Blinding of outcome as-
sessors
All outcomes
Low risk Judgement comment: blinding of the outcome assessors was referenced
in the paper reporting cardiovascular and cerebrovascular events in ADAPT
(ADAPT Research Group 2006). In the Data Collection paragraph of this paper,
the authors stated that, "masked study personnel recorded participant reports
of adverse events on data forms" (pg. e33).
ADAPT Research Group 2007/2006  (Continued)
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Low risk Quote: "As of December 17, 2004, ADAPT had recruited 2,528 participants. Fig-
ure 1 shows the flow of these participants from randomizations forward. Some
403 participants did not contribute to the analyses for one of three reasons: 1)
their observations were censored before their first annual follow-up (n=179);
2) they did not return for cognitive follow-up (n=210); or 3) no information on
cognition was available because they had refused or not completed a request-
ed Dementia Evaluation. These losses were distributed proportionally across
treatment groups (Fisher exact P = 0.54)" (pg.1802).
Quote: "In all instances, we used the principle of intention-to-treat (ITT) when




Low risk Judgement comment: outcomes were reported in 2 separate papers. The first
paper (The ADAPT Research Group 2007) reported the primary outcome, i.e. di-
agnosis of AD, and secondary outcomes, i.e. incidence of all-cause dementia
and MCI. Outcomes presented in the methods section were presented in the
results section. Adverse events were reported in a second paper (The ADAPT
Research Group 2006). All adverse events detailed in the methods section were
presented in the results section.
Other sources of bias Low risk Judgement comment: no other sources of bias apparent.
Funding: "Grant funding was received from the National Institute on Aging
(U01 AG15477). Celecoxib and matching placebo were provided by Pfizer, Inc.
Naproxen sodium and matching placebo were provided by Bayer Consumer
Healthcare" (pg. 1800).




Methods Study design: RCT.
Data collection time points: Trial participants had annual visits and six-monthly telephone calls. It
was planned that participants reaching the study endpoints for dementia or disability would then be
followed for the duration of the trial for mortality.
Participants Setting: Australia and the USA.
Inclusion criteria: community dwelling. Able to give informed consent. Able to attend a study visit.
Men and women aged ≥ 70 years (no upper age limit) except for US black and Hispanic people who
were aged ≥ 65 years (no upper age limit).
Exclusion criteria: history of cardiovascular or cerebrovascular event. Clinical diagnosis of atrial fibril-
lation, dementia, physical disability, condition associated with a high risk of bleeding, condition likely
to cause death within 5 years. Current continuous use of antiplatelet or anticoagulant medication. Cur-
rent use of aspirin for secondary prevention. Uncontrolled hypertension. Unwilling to cease regular as-
pirin being taken for primary prevention. Tablet taking compliance < 80% during a 4-week placebo run-
in phase. Current participation in another trial.
Participants randomised: total 19,114 (16,703 in Australia and 2411 in US), 9525 allocated aspirin and
9589 allocated placebo
Interventions Intervention: low-dose aspirin (100 mg daily)
Control: matching placebo
ASPREE 2018 
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Intervention delivered for median of 4.7 years, only 5 months ahead of the planned completion date.
Outcomes • Dementia diagnosed according to DSM-IV criteria.
• Mortality.
• Adverse events: major haemorrhage.
• Cardiovascular events, i.e. fatal coronary heart disease, non-fatal MI, fatal or non-fatal stroke, or hos-
pitalisation for heart failure.
• Diagnosis of MCI.
• ADL.
Identification Authors name: JJ McNeil
Institution: Monash University, Melbourne
E-mail: john.mcneill@monash.edu
Address: Department of Epidemiology and Preventative Medicine, Monash University, 553 St Kilda Rd,
Melbourne, VIC 30004, Australia
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Participants allocated according to a computer-generated randomisation
schedule.




Low risk Quote: "Trial participants, study staD, investigators, and general practitioner
associate investigators, were unaware of the trial group assignment until the
publication of this article" (pg. 3).
Blinding of outcome as-
sessors
All outcomes
Low risk All outcomes were adjudicated by an endpoint adjudication committee con-





Low risk Outcome analyses undertaken on an intention-to-treat basis.
Quote: "By the last 12 months of the trial, 82% of participants were still attend-
ing annual follow-up visits, 5.5% had died, 9.7% were still being followed-up
by regular telephone contact, or through access to clinical or other records,
1.2% had withdrawn, 1.6% were lost to follow-up. All participants contributed
data to the analyses until the time of withdrawal or loss to follow-up" (pg. 6).
Selective outcome report-
ing
Low risk Judgement comment: all outcomes detailed in the methods section were re-
ported in the results section.
Other sources of bias Low risk Funded by grants from (quote): "the National Institute on Aging and the Na-
tional Cancer Institute at the National Institutes of health, National Health and
Medical research Council of Australia and by Monash University and the Victo-
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Study characteristics
Methods Study design: RCT.
Data collection time points: baseline and 18-months for cognitive outcomes.
Participants Setting: university research institute, USA.
Inclusion criteria: aged ≥ 40 years with objective cognitive performance scores that were normal for
their age group. All had mild age-related memory complaints.
Exclusion criteria: taking drugs that could influence cognition (e.g. cholinesterase inhibitors, seda-
tive-hypnotics) or modify COX-2 drug safety (e.g. aspirin) or supplements that could have such effects
(e.g. phosphatidyl serine, ginkgo biloba). History of excessive alcohol or tobacco use. Evidence of de-
pression or scoring < 26 on the MMSE. Meeting diagnostic criteria for dementia, MCI or other major psy-
chiatric disorders.
Participants randomised: 88 who met the inclusion criteria completed baseline clinical assessments,
neuropsychological testing and scanning were randomised. 16 withdrew from participation after ran-
domisation but before initiation of treatment. Of remaining 72 participants, 36 were randomised to the
celecoxib group and 36 to the placebo group.
Interventions Intervention: celecoxib 200–400 mg BID.
Control: placebo.
Outcomes • Change in cognition from baseline across 6 cognitive domains: psychomotor speed, visuospatial func-
tioning, executive functioning, learning, delayed recall and language/semantic memory.
• Adverse events.
Identification Authors name: Dr Gary W Small
Institution: The Semel Institute
E-mail: gsmall@mednet.ucla.edu
Address: Suite 88–201, 760 Westwood Plaza, Los Angeles 90024, CA, USA.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Judgement comment: randomisation was undertaken using a randomisation
table.




Unclear risk Judgement comment: insufficient detail to make informed judgement.
Blinding of outcome as-
sessors
All outcomes




High risk Outcome analyses was not undertaken on an intention-to-treat basis.
Small 2008 
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Quote: "A total of 88 subjects, who met the study inclusion criteria complet-
ed baseline clinical assessments, neuropsychological testing, and scanning,
were randomized and 16 of them withdrew from participation after random-
ization but before initiation of treatment (Fig. 1). Of the remaining 72 subjects,
36 were randomized to the celecoxib group and 36 to the placebo group. Of
the subjects randomized, a total of 40 completed the study, 22 in the celecoxib
treatment arm and 18 in the placebo treatment arm. Subjects who withdrew
from the study did not differ significantly from those who completed the study
in mean age or baseline cognitive measures" (pg. 6).
Selective outcome report-
ing
Low risk Judgement comment: all outcomes detailed in the methods section were re-
ported in the results section.
Other sources of bias Low risk Funding bias: quote: "The University of California, Los Angeles, owns a U.S.
patent (6,274,119) entitled “Methods for Labeling β-Amyloid Plaques and Neu-
rofibrillary Tangles,” that has been licensed to Siemens. Drs. Small, Huang,
and Barrio are among the inventors, have received royalties, and will receive
royalties on future sales. Dr. Small reports having served as a consultant and/
or having received lecture fees from Abbott, Brainstorming Co., Dakim, Eisai,
Forest, Myriad Genetics, Novartis, Ortho-McNeil, Pfizer, Radica, Siemens, and
VerusMed. Dr. Small also reports having received stock options from Dakim.
Dr. Lavretsky reports having received lecture fees from Eisai, Janssen, and Pfiz-
er and having received a grant from Forest. Dr. Huang reports having received
lecture fees from GlaxoSmithKline. Dr. Barrio reports having served as a con-
sultant and having received lecture fees from Nihon Medi-Physics Co, Bris-
tol-Meyer Squibb, PETNet Pharmaceuticals, and Siemens. Drs. Ercoli, Siddarth,





Methods Study design: RCT.
Data collection time points: baseline, 1 month and every 4 months or at discontinuation from the tri-
al. Study was expected to run over 4 years. However, the study was terminated in April 2003, 11 months
earlier than the planned termination date because Merck announced the voluntary worldwide with-
drawal of rofecoxib from the market.
Participants Setting: 46 sites across the USA.
Inclusion criteria: people aged ≥ 65 years who had completed ≥ 8 grades of education, and had a reli-
able informant who could accompany them to each clinic visit. Patients screened at study sites to de-
termine if they met all the following criteria for MCI: patient-reported memory problem, or informant
reports that patient has memory problem; informant reported that patient's memory had declined in
the past year; MMSE score ≥ 24; CDR global score 0.5 with Memory Domain score ≥ 0.5; BDRS total score
≤ 3.5, with no part 1 item score > 0.5; Auditory Verbal Learning Test total score ≤ 37.
Exclusion criteria: dementia. Inadequate motor or sensory capacities to comply with testing. Modified
Hachinski Ischemic Scale score > 4; Hamilton Depression Scale (17-item version) score > 13 (to exclude
people whose cognitive impairment may have been related to depression). History of angina or CHF
with symptoms that occurred at res. Uncontrolled hypertension. History within past year of MI, coro-
nary artery bypass, angioplasty or stent placement History within the past 2 years of stroke, multiple
lacunar infarcts or TIA events. History within the past 3 months of gastrointestinal bleeding. Expected
therapeutic need for chronic NSAID or oestrogen replacement therapy during study. Taking NSAIDs on
a chronic basis (≥ 7 days per month for the 2 months prior to study entry). Taking oestrogen replace-
ment therapy (excluding topical ointments) within 2 months of study entry or cholinesterase inhibitors
within 1 month of study entry.
Thal 2005 
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Participants randomised: total 1457, of whom, 725 were allocated rofecoxib and 732 were allocat-
ed placebo. The authors reported that of total number of participants allocated rofecoxib, 34.3% were
women and of total number of participants allocated placebo, 31.1% were women.
Interventions Intervention: rofecoxib 25 mg once daily
Control: placebo
Median duration for study participation: 115 weeks in rofecoxib group and 130 weeks in placebo group.
Outcomes Outcome relevant to this review:
• Clinical diagnosis of dementia. Diagnosis of possible or probable dementia was diagnosed according
to the NINCDS-ADRDA criteria.
• Adverse events.
• Mortality.
• ADL as measured by the BDRS (higher scores across Part 1 and Part 2 indicated greater impairment).
Identification Authors name: Dr CR Lines
Institution: Merck Research Laboratories
E-mail: chris_lines@merck.com
Address: 10 Sentry Parkway, Blue Bell, PA 19422, USA.
Notes  
Risk of bias
Bias Authors' judgement Support for judgement
Sequence generation Low risk Quote: "Randomization of patients at each study site was determined by a
computer-generated allocation schedule" (pg. 1205).
Allocation concealment Unclear risk Quote: "The allocation schedule was generated by a statistician at Merck Re-
search Laboratories according to in-house blinding conditions" (pg. 1205).




Low risk Quote: "The rofecoxib and placebo tablets were visually identical" (pg. 1205).
Blinding of outcome as-
sessors
All outcomes
Low risk Quote: "For patients who reached the end point of clinically diagnosed demen-
tia, all relevant data were sent to an independent blinded adjudication com-




Low risk Quote: "The analysis was based on a Cox proportional hazards model of time-
to-event data (based on the initial diagnosis of AD) using an intention-to-treat
approach, which included all randomised patients regardless of whether or
not they were taking study medication" (pg. 1206).
656 participants discontinued treatment, 324 in rofecoxib group and 331 in
placebo group. Loss to follow-up in each group was comparable.
Judgement comments: high non-completion rates but primary efficacy analy-
sis by intention-to-treat.
Thal 2005  (Continued)
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Selective outcome report-
ing
Low risk Judgement comment: a comparison of outcomes of interest reported in the
methods section were consistent with those reported in the results section of
the trial publication.
Other sources of bias Low risk Judgement comment: low risk.
Funding: "This study was funded by Merck Research Laboratories. SH Fer-
ris was a paid consultant for Merck Research Laboratories on this study. L
Kirby received funding from Merck Research Laboratories to participate in
this study. GA Block, CR Lines, E Yuen, C Assaid, ML Nessly, BA Norman, CC
Baranak, and SA Reines were employees of Merck Research Laboratories at
the time the study was performed (GA Block is currently an employee of Astra
Zeneca, and SA Reines and E Yuen are currently employees of Johnson & John-
son)" (pg. 1213).
Judgement comment: trial outcomes were not favourable to drug being tested
so we deemed it unlikely that funding bias was an issue in this trial.
Thal 2005  (Continued)
AD: Alzheimer's disease; ADAPT: Alzheimer's Disease Anti-inflammatory Prevention Trial; ADL: activities of daily living; ASPREE: Aspirin in
Reducing Events in the Elderly; BDRS: Blessed Dementia Rating Scale; BID: twice daily; CDR: Clinical Dementia Rating; CHF: congestive heart
failure; COX: cyclo-oxygenase; DSM-IV: Diagnostic and Statistical Manual of Mental Disorders-IV criteria; MCI: mild cognitive impairment;
MI: myocardial infarction; MMSE: Mini-Mental State Examination; NINCDS-ADRDA: Neurological and Communicative Disorders and Stroke
– Alzheimer's Disease and Related Disorders Association Criteria; NSAIDs: non-steroidal anti-inflammatory drugs; RCT: randomised
controlled trial; SRT: Selective Recall Test; TIA: transient ischaemic attack.
 
Characteristics of excluded studies [ordered by study ID]
 
Study Reason for exclusion
ADAPT-FS Research Group
2015
Study design did not meet inclusion criteria, i.e. not an RCT or CCT. Follow-up study to ADAPT trial.
Arai 2011 Study design did not meet inclusion criteria, i.e. not an RCT or CCT. A discussion paper on preven-
tion and treatment strategies for dementia.
Arvanitakis 2008 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Bertozzi 1996 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Breitner 2009 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Broe 2000 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Bruce-Jones 1994 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Clarke 2003 Population did not meet inclusion criteria, participants had dementia.
Gómez-Isla 2008 Intervention did not meet the inclusion criteria, i.e. aspirin or NSAID.
Hayden 2007 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Ibáñez-Hernández 2008 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Jonker 2003 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
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Study Reason for exclusion
Kang 2007 Study design did not meet the inclusion criteria, i.e. not an RCT or CCT. 'A cohort study' within an
RCT.
Kern 2012 Study design did not meet inclusion criteria, i.e. not an RCT or CCT. A prospective, popula-
tion-based cohort study
Kerst 2002 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Marini 2013 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
May 1992 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Price 2008 Contained none of the prespecified outcomes for this review.
Rist 2013 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Silagy 1993 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Sonnen 2010 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
Szekely 2008 Study design did not meet inclusion criteria, i.e. not an RCT or CCT.
CCT: controlled clinical trial; RCT: randomised controlled trial.
 
 
D A T A   A N D   A N A L Y S E S
 
Comparison 1.   Aspirin compared with placebo





Statistical method Effect size
1.1 Incidence of dementia 1 19114 Risk Ratio (M-H, Fixed, 95% CI) 0.98 [0.83, 1.15]
1.2 Adverse events (haemorrhage) 1 19114 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.17, 1.60]
1.3 Mortality 1 19114 Risk Ratio (M-H, Fixed, 95% CI) 1.14 [1.01, 1.28]
1.4 Activities of daily living 1 19114 Risk Ratio (M-H, Fixed, 95% CI) 0.84 [0.70, 1.02]
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Test for overall effect: Z = 0.30 (P = 0.76)



















M-H, Fixed, 95% CI
0.98 [0.83 , 1.15]
0.98 [0.83 , 1.15]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours aspirin Favours placebo
 
 






Test for overall effect: Z = 3.97 (P < 0.0001)



















M-H, Fixed, 95% CI
1.37 [1.17 , 1.60]
1.37 [1.17 , 1.60]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours aspirin Favours placebo
 
 






Test for overall effect: Z = 2.14 (P = 0.03)



















M-H, Fixed, 95% CI
1.14 [1.01 , 1.28]
1.14 [1.01 , 1.28]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours aspirin Favours placebo
 
 






Test for overall effect: Z = 1.72 (P = 0.09)



















M-H, Fixed, 95% CI
0.84 [0.70 , 1.02]
0.84 [0.70 , 1.02]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours aspirin Favours placebo
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Comparison 2.   NSAIDs compared with placebo: cognitively healthy adults with a family history of Alzheimer's
disease (AD)





Statistical method Effect size
2.1 Incidence of dementia (AD) 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.1.1 All NSAIDs (celecoxib and naproxen
combined)
1 2125 Risk Ratio (M-H, Fixed, 95% CI) 1.91 [0.89, 4.10]
2.1.2 Celecoxib 1 1527 Risk Ratio (M-H, Fixed, 95% CI) 1.79 [0.75, 4.30]
2.1.3 Naproxen 1 1506 Risk Ratio (M-H, Fixed, 95% CI) 2.02 [0.86, 4.78]
2.2 All-cause dementia 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.2.1 All NSAIDs (celecoxib and naproxen
combined)
1 2118 Risk Ratio (M-H, Fixed, 95% CI) 2.45 [1.05, 5.68]
2.2.2 Celecoxib 1 1523 Risk Ratio (M-H, Fixed, 95% CI) 2.50 [0.99, 6.32]
2.2.3 Naproxen 1 1499 Risk Ratio (M-H, Fixed, 95% CI) 2.39 [0.93, 6.12]
2.3 Adverse effects – cardiovascular: my-
ocardial infarction
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.3.1 All NSAIDs (Celecoxib and Naproxen
combined)
1 2500 Risk Ratio (M-H, Fixed, 95% CI) 1.21 [0.61, 2.40]
2.3.2 Celecoxib 1 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.92 [0.38, 2.20]
2.3.3 Naproxen 1 1783 Risk Ratio (M-H, Fixed, 95% CI) 1.50 [0.70, 3.22]
2.4 Adverse effects – stroke 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.4.1 All NSAIDs (celecoxib and naproxen
combined)
1 2500 Risk Ratio (M-H, Fixed, 95% CI) 1.82 [0.76, 4.37]
2.4.2 Celecoxib 1 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.49 [0.53, 4.24]
2.4.3 Naproxen 1 1783 Risk Ratio (M-H, Fixed, 95% CI) 2.14 [0.82, 5.61]
2.5 Adverse effects – congestive heart fail-
ure
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.5.1 All NSAIDs (celecoxib and naproxen
combined)
1 2500 Risk Ratio (M-H, Fixed, 95% CI) 1.18 [0.46, 3.02]
2.5.2 Celecoxib 1 1787 Risk Ratio (M-H, Fixed, 95% CI) 0.64 [0.17, 2.47]
2.5.3 Naproxen 1 1783 Risk Ratio (M-H, Fixed, 95% CI) 1.72 [0.62, 4.71]
2.6 Adverse effects – transient ischaemic
attack
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
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Statistical method Effect size
2.6.1 All NSAIDs (celecoxib and naproxen
combined)
1 2500 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.58, 2.77]
2.6.2 Celecoxib 1 1787 Risk Ratio (M-H, Fixed, 95% CI) 1.19 [0.47, 3.01]
2.6.3 Naproxen 1 1783 Risk Ratio (M-H, Fixed, 95% CI) 1.35 [0.55, 3.31]
2.7 Adverse effects – antihypertensive ther-
apy
1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.7.1 All NSAIDs (celecoxib and naproxen
combined)
1 1521 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [1.17, 1.61]
2.7.2 Celecoxib 1 1084 Risk Ratio (M-H, Fixed, 95% CI) 1.43 [1.19, 1.71]
2.7.3 Naproxen 1 1081 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.10, 1.59]
2.8 Mortality 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.8.1 All NSAIDs (celecoxib and naproxen
combined)
1 2528 Risk Ratio (M-H, Fixed, 95% CI) 1.37 [0.78, 2.43]
2.8.2 Celecoxib 1 1809 Risk Ratio (M-H, Fixed, 95% CI) 1.41 [0.73, 2.72]
2.8.3 Naproxen 1 1802 Risk Ratio (M-H, Fixed, 95% CI) 1.34 [0.69, 2.61]
2.9 Cognitive decline from baseline 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
2.9.1 All NSAIDs (celecoxib and naproxen
combined)
1 2072 Risk Ratio (M-H, Fixed, 95% CI) 1.28 [0.72, 2.28]
2.9.2 Celecoxib 1 1490 Risk Ratio (M-H, Fixed, 95% CI) 1.30 [0.67, 2.53]
2.9.3 Naproxen 1 1467 Risk Ratio (M-H, Fixed, 95% CI) 1.27 [0.64, 2.49]
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Analysis 2.1.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults
with a family history of Alzheimer's disease (AD), Outcome 1: Incidence of dementia (AD)
Study or Subgroup
2.1.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 1.65 (P = 0.10)
2.1.2 Celecoxib




Test for overall effect: Z = 1.31 (P = 0.19)
2.1.3 Naproxen




Test for overall effect: Z = 1.61 (P = 0.11)







































M-H, Fixed, 95% CI
1.91 [0.89 , 4.10]
1.91 [0.89 , 4.10]
1.79 [0.75 , 4.30]
1.79 [0.75 , 4.30]
2.02 [0.86 , 4.78]
2.02 [0.86 , 4.78]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
 
 
Analysis 2.2.   Comparison 2: NSAIDs compared with placebo: cognitively healthy
adults with a family history of Alzheimer's disease (AD), Outcome 2: All-cause dementia
Study or Subgroup
2.2.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 2.08 (P = 0.04)
2.2.2 Celecoxib




Test for overall effect: Z = 1.94 (P = 0.05)
2.2.3 Naproxen











































M-H, Fixed, 95% CI
2.45 [1.05 , 5.68]
2.45 [1.05 , 5.68]
2.50 [0.99 , 6.32]
2.50 [0.99 , 6.32]
2.39 [0.93 , 6.12]
2.39 [0.93 , 6.12]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
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Analysis 2.3.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a family
history of Alzheimer's disease (AD), Outcome 3: Adverse e9ects – cardiovascular: myocardial infarction
Study or Subgroup
2.3.1 All NSAIDs (Celecoxib and Naproxen combined)




Test for overall effect: Z = 0.54 (P = 0.59)
2.3.2 Celecoxib




Test for overall effect: Z = 0.19 (P = 0.85)
2.3.3 Naproxen




Test for overall effect: Z = 1.04 (P = 0.30)







































M-H, Fixed, 95% CI
1.21 [0.61 , 2.40]
1.21 [0.61 , 2.40]
0.92 [0.38 , 2.20]
0.92 [0.38 , 2.20]
1.50 [0.70 , 3.22]
1.50 [0.70 , 3.22]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
 
 
Analysis 2.4.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults
with a family history of Alzheimer's disease (AD), Outcome 4: Adverse e9ects – stroke
Study or Subgroup
2.4.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 1.34 (P = 0.18)
2.4.2 Celecoxib




Test for overall effect: Z = 0.75 (P = 0.45)
2.4.3 Naproxen




Test for overall effect: Z = 1.55 (P = 0.12)







































M-H, Fixed, 95% CI
1.82 [0.76 , 4.37]
1.82 [0.76 , 4.37]
1.49 [0.53 , 4.24]
1.49 [0.53 , 4.24]
2.14 [0.82 , 5.61]
2.14 [0.82 , 5.61]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
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Analysis 2.5.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a
family history of Alzheimer's disease (AD), Outcome 5: Adverse e9ects – congestive heart failure
Study or Subgroup
2.5.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 0.34 (P = 0.74)
2.5.2 Celecoxib




Test for overall effect: Z = 0.65 (P = 0.52)
2.5.3 Naproxen




Test for overall effect: Z = 1.05 (P = 0.30)







































M-H, Fixed, 95% CI
1.18 [0.46 , 3.02]
1.18 [0.46 , 3.02]
0.64 [0.17 , 2.47]
0.64 [0.17 , 2.47]
1.72 [0.62 , 4.71]
1.72 [0.62 , 4.71]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
 
 
Analysis 2.6.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a
family history of Alzheimer's disease (AD), Outcome 6: Adverse e9ects – transient ischaemic attack
Study or Subgroup
2.6.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 0.61 (P = 0.54)
2.6.2 Celecoxib




Test for overall effect: Z = 0.38 (P = 0.71)
2.6.3 Naproxen




Test for overall effect: Z = 0.66 (P = 0.51)







































M-H, Fixed, 95% CI
1.27 [0.58 , 2.77]
1.27 [0.58 , 2.77]
1.19 [0.47 , 3.01]
1.19 [0.47 , 3.01]
1.35 [0.55 , 3.31]
1.35 [0.55 , 3.31]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
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Analysis 2.7.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with a
family history of Alzheimer's disease (AD), Outcome 7: Adverse e9ects – antihypertensive therapy
Study or Subgroup
2.7.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 3.90 (P < 0.0001)
2.7.2 Celecoxib




Test for overall effect: Z = 3.86 (P = 0.0001)
2.7.3 Naproxen




Test for overall effect: Z = 2.92 (P = 0.003)







































M-H, Fixed, 95% CI
1.37 [1.17 , 1.61]
1.37 [1.17 , 1.61]
1.43 [1.19 , 1.71]
1.43 [1.19 , 1.71]
1.32 [1.10 , 1.59]
1.32 [1.10 , 1.59]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
 
 
Analysis 2.8.   Comparison 2: NSAIDs compared with placebo: cognitively healthy
adults with a family history of Alzheimer's disease (AD), Outcome 8: Mortality
Study or Subgroup
2.8.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 1.09 (P = 0.27)
2.8.2 Celecoxib




Test for overall effect: Z = 1.02 (P = 0.31)
2.8.3 Naproxen




Test for overall effect: Z = 0.86 (P = 0.39)







































M-H, Fixed, 95% CI
1.37 [0.78 , 2.43]
1.37 [0.78 , 2.43]
1.41 [0.73 , 2.72]
1.41 [0.73 , 2.72]
1.34 [0.69 , 2.61]
1.34 [0.69 , 2.61]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
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Analysis 2.9.   Comparison 2: NSAIDs compared with placebo: cognitively healthy adults with
a family history of Alzheimer's disease (AD), Outcome 9: Cognitive decline from baseline
Study or Subgroup
2.9.1 All NSAIDs (celecoxib and naproxen combined)




Test for overall effect: Z = 0.85 (P = 0.39)
2.9.2 Celecoxib




Test for overall effect: Z = 0.77 (P = 0.44)
2.9.3 Naproxen




Test for overall effect: Z = 0.69 (P = 0.49)







































M-H, Fixed, 95% CI
1.28 [0.72 , 2.28]
1.28 [0.72 , 2.28]
1.30 [0.67 , 2.53]
1.30 [0.67 , 2.53]
1.27 [0.64 , 2.49]
1.27 [0.64 , 2.49]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours placebo
 
 
Comparison 3.   NSAIDs compared with placebo: adults with age-related memory loss





Statistical method Effect size
3.1 Adverse events – gastrointestinal 1 40 Risk Ratio (M-H, Fixed, 95% CI) 2.66 [1.05, 6.75]
3.2 Cognitive decline from baseline
(Psychomotor Speed)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.2.1 Trailmaking A Digital Symbol 1 40 Mean Difference (IV, Fixed, 95% CI) 2.40 [-3.41, 8.21]
3.2.2 WAIS II Digital Symbol 1 40 Mean Difference (IV, Fixed, 95% CI) -5.00 [-16.30, 6.30]
3.3 Cognitive decline from baseline (Vi-
suospatial Functioning)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.3.1 WAIS-III Block Design 1 40 Mean Difference (IV, Fixed, 95% CI) -0.70 [-7.35, 5.95]
3.3.2 Complex Figure, Copy 1 40 Mean Difference (IV, Fixed, 95% CI) 0.20 [-1.72, 2.12]
3.4 Cognitive decline from baseline
(Executive Functioning)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.4.1 Trailmaking B 1 40 Mean Difference (IV, Fixed, 95% CI) 7.20 [-17.85, 32.25]
3.4.2 Stroop Interference 1 40 Mean Difference (IV, Fixed, 95% CI) -4.40 [-29.42, 20.62]
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Statistical method Effect size
3.4.3 F.A.S. Letter Fluency 1 40 Mean Difference (IV, Fixed, 95% CI) -3.30 [-13.80, 7.20]
3.5 Cognitive decline (Learning) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.5.1 Selective Reminding, Total Recall 1 40 Mean Difference (IV, Fixed, 95% CI) -7.70 [-19.26, 3.86]
3.5.2 Verbal Paired Associations 1 1 40 Mean Difference (IV, Fixed, 95% CI) -0.90 [-6.09, 4.29]
3.5.3 Benton Visual Retention 1 40 Mean Difference (IV, Fixed, 95% CI) -0.40 [-2.26, 1.46]
3.6 Cognitive decline (Delayed Recall) 1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.6.1 Selective Reminding, Delayed Re-
call
1 40 Mean Difference (IV, Fixed, 95% CI) -1.50 [-3.18, 0.18]
3.6.2 Complex Figure Recall 1 40 Mean Difference (IV, Fixed, 95% CI) 0.50 [-4.23, 5.23]
3.6.3 Verbal Paired Associations II 1 40 Mean Difference (IV, Fixed, 95% CI) -0.70 [-2.19, 0.79]
3.7 Cognitive decline (Language/Se-
mantic Memory)
1   Mean Difference (IV, Fixed, 95% CI) Subtotals only
3.7.1 Boston Naming 1 40 Mean Difference (IV, Fixed, 95% CI) -0.20 [-3.15, 2.75]
3.7.2 Animal Naming 1 40 Mean Difference (IV, Fixed, 95% CI) 3.10 [-0.31, 6.51]
 
 
Analysis 3.1.   Comparison 3: NSAIDs compared with placebo: adults with






Test for overall effect: Z = 2.06 (P = 0.04)



















M-H, Fixed, 95% CI
2.66 [1.05 , 6.75]
2.66 [1.05 , 6.75]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAID Favours placebo
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Analysis 3.2.   Comparison 3: NSAIDs compared with placebo: adults with age-related
memory loss, Outcome 2: Cognitive decline from baseline (Psychomotor Speed)
Study or Subgroup




Test for overall effect: Z = 0.81 (P = 0.42)



































IV, Fixed, 95% CI
2.40 [-3.41 , 8.21]
2.40 [-3.41 , 8.21]
-5.00 [-16.30 , 6.30]
-5.00 [-16.30 , 6.30]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
 
 
Analysis 3.3.   Comparison 3: NSAIDs compared with placebo: adults with age-related
memory loss, Outcome 3: Cognitive decline from baseline (Visuospatial Functioning)
Study or Subgroup




Test for overall effect: Z = 0.21 (P = 0.84)




Test for overall effect: Z = 0.20 (P = 0.84)































IV, Fixed, 95% CI
-0.70 [-7.35 , 5.95]
-0.70 [-7.35 , 5.95]
0.20 [-1.72 , 2.12]
0.20 [-1.72 , 2.12]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
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Analysis 3.4.   Comparison 3: NSAIDs compared with placebo: adults with age-related











Test for overall effect: Z = 0.34 (P = 0.73)




Test for overall effect: Z = 0.62 (P = 0.54)









































IV, Fixed, 95% CI
7.20 [-17.85 , 32.25]
7.20 [-17.85 , 32.25]
-4.40 [-29.42 , 20.62]
-4.40 [-29.42 , 20.62]
-3.30 [-13.80 , 7.20]
-3.30 [-13.80 , 7.20]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
 
 
Analysis 3.5.   Comparison 3: NSAIDs compared with placebo: adults
with age-related memory loss, Outcome 5: Cognitive decline (Learning)
Study or Subgroup




Test for overall effect: Z = 1.31 (P = 0.19)




Test for overall effect: Z = 0.34 (P = 0.73)




Test for overall effect: Z = 0.42 (P = 0.67)









































IV, Fixed, 95% CI
-7.70 [-19.26 , 3.86]
-7.70 [-19.26 , 3.86]
-0.90 [-6.09 , 4.29]
-0.90 [-6.09 , 4.29]
-0.40 [-2.26 , 1.46]
-0.40 [-2.26 , 1.46]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
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Analysis 3.6.   Comparison 3: NSAIDs compared with placebo: adults with
age-related memory loss, Outcome 6: Cognitive decline (Delayed Recall)
Study or Subgroup




Test for overall effect: Z = 1.75 (P = 0.08)




Test for overall effect: Z = 0.21 (P = 0.84)




Test for overall effect: Z = 0.92 (P = 0.36)









































IV, Fixed, 95% CI
-1.50 [-3.18 , 0.18]
-1.50 [-3.18 , 0.18]
0.50 [-4.23 , 5.23]
0.50 [-4.23 , 5.23]
-0.70 [-2.19 , 0.79]
-0.70 [-2.19 , 0.79]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
 
 
Analysis 3.7.   Comparison 3: NSAIDs compared with placebo: adults with age-










































IV, Fixed, 95% CI
-0.20 [-3.15 , 2.75]
-0.20 [-3.15 , 2.75]
3.10 [-0.31 , 6.51]
3.10 [-0.31 , 6.51]
Mean Difference
IV, Fixed, 95% CI
-100 -50 0 50 100
Favours NSAID Favours placebo
 
 
Comparison 4.   NSAIDs compared with placebo: mild cognitive impairment





Statistical method Effect size
4.1 Incidence of dementia 1 1457 Risk Ratio (M-H, Fixed, 95% CI) 1.32 [1.01, 1.72]
4.2 Adverse events 1   Risk Ratio (M-H, Fixed, 95% CI) Subtotals only
4.2.1 Cardiovascular 1 1457 Risk Ratio (M-H, Fixed, 95% CI) 1.07 [0.68, 1.66]
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Statistical method Effect size
4.2.2 Gastrointestinal 1 1457 Risk Ratio (M-H, Fixed, 95% CI) 3.53 [1.17, 10.68]
4.3 Mortality 1 1457 Risk Ratio (M-H, Fixed, 95% CI) 1.62 [0.85, 3.05]
 
 
Analysis 4.1.   Comparison 4: NSAIDs compared with placebo:






Test for overall effect: Z = 2.01 (P = 0.04)



















M-H, Fixed, 95% CI
1.32 [1.01 , 1.72]
1.32 [1.01 , 1.72]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours Placebo
 
 










































M-H, Fixed, 95% CI
1.07 [0.68 , 1.66]
1.07 [0.68 , 1.66]
3.53 [1.17 , 10.68]
3.53 [1.17 , 10.68]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours Placebo
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Test for overall effect: Z = 1.48 (P = 0.14)



















M-H, Fixed, 95% CI
1.62 [0.85 , 3.05]
1.62 [0.85 , 3.05]
Risk Ratio
M-H, Fixed, 95% CI
0.01 0.1 1 10 100
Favours NSAIDs Favours Placebo
 
 
A P P E N D I C E S
Appendix 1. Sources searched and search strategies
 





(Date of most recent
search: 9 January
2020)
aspirin OR "cyclooxygenase 2 inhibitor" OR aceclofenac OR acemetacin OR cele-
coxib OR dexibruprofen OR dexketoprofen OR diclofenac sodium OR diflunisal OR
diflusinal OR etodolac OR etoricoxib OR fenbufen OR fenoprofen OR flurbiprofen
OR ibuprofen OR indometacin OR indomethacin OR ketoprofen OR lumiracoxib OR
mefenamic OR meloxicam OR nabumetone OR naproxen OR nimesulide OR "anti-in-
flammatory" OR piroxicam OR sulindac OR tenoxicam OR tiaprofenic acid OR triam-











(Date of most recent
search: 9 January
2020)
#1 MeSH descriptor: [Aspirin] explode all trees
#2 aspirin
#3 "acetylsalicylic acid"
#4 #1 or #2 or #3
#5 MeSH descriptor: [Anti-Inflammatory Agents, Non-Steroidal] explode all trees
#6 "anti-inflammatory"
#7 #5 or #6





#13 MeSH descriptor: [Cognition] explode all trees
#14 MeSH descriptor: [Dementia] explode all trees
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#16 MeSH descriptor: [Secondary Prevention] explode all trees
#17 #9 or #10 or #11 or #12 or #13 or #14 or #15 or #16
#18 #8 and #17 in Trials
MEDLINE Epub
Ahead of Print, In-















































Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia (Review)


































56. (cognition or cognitive).ti,ab.
57. Cognition/
58. Cognition Disorders/





64. (cognit* adj3 health*).ti,ab.
65. "older adult*".ti,ab.
  (Continued)
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71. 53 and 70
72. randomized controlled trial.pt.
73. controlled clinical trial.pt.




78. (animals not (humans and animals)).sh.
79. 77 not 78
80. 71 and 79
81. 54 or 55 or 56 or 57 or 58 or 60 or 61 or 62 or 64
82. 63 or 65 or 66 or 67 or 68 or 69
83. 53 and 79 and 81 and 82
84. 55 and 59
85. 53 and 59 and 79
86. 84 or 85
EMBASE (OvidSP)
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56. (cognition or cognitive).ti,ab.
57. Cognition/
58. Cognition Disorders/





64. (cognit* adj3 health*).ti,ab.
65. "older adult*".ti,ab.





71. 53 and 70
72. 54 or 55 or 56 or 57 or 58 or 60 or 61 or 62 or 64
73. 63 or 65 or 66 or 67 or 68 or 69
74. randomly.ab.
75. randomized controlled trial/
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82. 53 and 72 and 73 and 81
83. primary prevention/
84. secondary prevention/
85. 83 or 84
86. 53 and 81 and 85
87. 54 or 55 or 57 or 64
88. 86 and 87
89. 82 or 88
PSYCINFO (OvidSP)
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49. 35 and 48






56. "randomised control* trial".ti,ab.
57. "randomized control* trial".ti,ab.
58. or/50-57
59. 49 and 58
CINAHL (EBSCOhost) S1 TX aspirin Jan 2015: 30
  (Continued)
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(Date of most recent
search: 9 January
2020)
S2 TX "cyclooxygenase 2 inhibitor*”
S3 TX "anti-inflammatory agent*"





S9 TX dexamenthasone OR TX dexibruprofen
S10 TX dexketoprofen
S11 TX “diclofenac sodium”
S12 TX diflunisal OR TX diflusinal
S13 TX etodolac OR TX etoricoxib






S20 TX Ketoprofen OR TX lumiracoxib
S21 TX “mefenamic acid” OR TX meloxicam
S22 TX methylprednisolone OR TX nabumetone
S23 TX naproxen OR TX nimesulide
S24 “non-steroid* anti-inflammatory agent*”
S25 TX prednisone OR TX piroxicam
S26 TX sulindac
S27 TX tenoxicam
S28 TX tiaprofenic acid OR TX triamcinolone
S29 (MH “Aspirin”)
S30 (MH "Antiinflammatory Agents, Non-Steroidal") OR (MH "Antiinflammatory
Agents, Steroidal”)
S31 S1 or S2 or S3 or S4 or S5 or S6 or S7 or S8 or S9 or S10 or S11 or S12 or S13 or
S14 or S15 or S16 or S17 or S18 or S19 or S20 or S21 or S22 or S23 or S24 or S25 or
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S35 (MH “Dementia”)
S36 TX elderly
S37 TX “old* adults”
S38 TX “aged adults”
S39 TX “aged sample”
S40 (MH "Aged") OR (MH "Aged, 80 and Over”)
S41 TX "middle age*”
S42 (MH “Middle Age”)





S48 AB “random* allocat*”
S49 AB “random* divide*”
S50 AB “allocat* random*”
S51 S32 OR S33 OR S34 OR S35
S52 S36 OR S37 OR S38 OR S39 OR S40 OR S41 OR S42
S53 S43 OR S44 OR S45 OR S46 OR S47 OR S48 OR S49 OR S50
S54 S31 AND S51 AND S52 AND S53
S55 (MH "Preventive Health Care")
S56 S31 AND S53 AND S55
S57 S54 OR S56
ISI Web of Science –
core collection
(Date of most recent
search: 9 January
2020)
TOPIC: (aspirin OR "acetylsalicylic acid" OR "anti-inflammatory agent*" OR NSAID*)
AND TOPIC: ("old* age*" OR "middle age*" OR elderly OR "old* adults" OR seniors
OR "senior citizens" OR "community dwelling") AND TOPIC: (randomly OR ran-
domised OR randomized OR RCT OR "controlled trial" OR "double blind" OR "single
blind") AND TOPIC: (cognition OR "prevent* dement*" OR "prevent alzheimer*" OR








(Date of most recent
search: 9 January
2020)
aspirin OR “agentes antiagregantes” OR “acetylsalicylic acid” OR “anti-inflamma-
tory” OR NSAID$ OR “cyclooxygenase 2 inhibitor$” OR ibuprofen OR naproxen OR
COX-2 OR rofecoxib [Words] and dementia OR elderly OR cognition OR "old$ adult$"
OR cognitive OR anciano OR demencia OR cognición [Words] and and trial OR group
OR randomly OR randomised OR randomized OR RCT OR "double blind" OR "sin-
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(Date of most recent
search: 9 January
2020)
([condition] dementia OR cognitive OR cognition OR elderly OR memory OR
alzheimer* OR MCI) AND ([interventions] aspirin OR "acetylsalicylic acid" OR "cy-










(Date of most recent
search: 9 January
2020)
([condition] dementia OR cognitive OR cognition OR elderly OR memory OR
alzheimer* OR MCI) AND ([interventions] aspirin OR acetylsalicylic acid OR cyclooxy-







TOTAL before deduplication 3627
TOTAL after deduplication 2207
  (Continued)
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Internal sources
• National University of Ireland, Galway, Ireland
External sources
• Health Research Board, Ireland
• NIHR, UK
This review was supported by the National Institute for Health Research (NIHR), via Cochrane Infrastructure funding to the Cochrane
Dementia and Cognitive Improvement group. The views and opinions expressed therein are those of the authors and do not necessarily
reflect those of the Systematic Reviews Programme, NIHR, National Health Service or the Department of Health
D I F F E R E N C E S   B E T W E E N   P R O T O C O L   A N D   R E V I E W
We included the primary outcome, incidence of dementia, which included all types of dementia. Where diDering dementia diagnoses were
presented, we favoured AD as this is the pathology thought to be most closely related to inflammation.
For the comparator 'other NSAIDs compared with placebo', we included three 'Summary of findings' tables reflecting the diDerent
populations included for this comparator. We had not prespecified initiation of antihypertensive therapy as an outcome of interest in the
protocol (Jordan 2015), but decided to include this under the adverse events outcome because of the importance of hypertension as a
risk factor for dementia.
We performed no subgroup or sensitivity analyses due to the small number of included studies.
I N D E X   T E R M S
Medical Subject Headings (MeSH)
Activities of Daily Living;  Alzheimer Disease  [epidemiology]  [prevention & control];  Anti-Inflammatory Agents, Non-Steroidal
 [administration & dosage]  [adverse eDects]  [*therapeutic use];  Aspirin  [administration & dosage]  [adverse eDects]  [*therapeutic
use];  Celecoxib  [administration & dosage]  [adverse eDects]  [therapeutic use];  Cyclooxygenase 2 Inhibitors  [administration &
dosage]  [adverse eDects]  [therapeutic use];  Dementia  [epidemiology]  [mortality]  [*prevention & control];  Hemorrhage  [chemically
induced]  [epidemiology];  Incidence;  Lactones  [therapeutic use];  Myocardial Infarction  [epidemiology];  Naproxen  [therapeutic use]; 
Randomized Controlled Trials as Topic;  Stroke  [epidemiology];  Sulfones  [therapeutic use]
MeSH check words
Adult; Aged; Aged, 80 and over; Humans; Middle Aged
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